<SEC-DOCUMENT>0001104659-23-018577.txt : 20230210
<SEC-HEADER>0001104659-23-018577.hdr.sgml : 20230210
<ACCEPTANCE-DATETIME>20230210162644
ACCESSION NUMBER:		0001104659-23-018577
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230210
FILED AS OF DATE:		20230210
DATE AS OF CHANGE:		20230210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		23612420

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm236242d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
<BR>
</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of February 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: </B></FONT><B><FONT STYLE="font-size: 14pt">001-39446</FONT></B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="text-align: center; width: 14%">
    <FONT STYLE="font-family: Wingdings">&#120;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="text-align: center; width: 14%">
<FONT STYLE="font-family: Wingdings"></FONT><!-- Field: Rule-Page --><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;<!-- Field: /Rule-Page --></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 10, 2023, CureVac N.V. (the &ldquo;Company&rdquo;)
completed an offering of 27,027,028 common shares, pursuant to an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with
Goldman Sachs &amp; Co. LLC, Jefferies LLC and SVB Securities LLC, as representatives of the several underwriters named therein. The Underwriting
Agreement includes the terms and conditions for the offering and sale of the securities, indemnification and contribution obligations
of the Company and the underwriters, including with respect to liabilities under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and other terms and conditions customary in agreements of this type. The foregoing description of the Underwriting Agreement
does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is attached to this
Report on Form 6-K as Exhibit 1.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The common shares have been registered under the
Securities Act pursuant to a registration statement on Form F-3 (File No. 333-259613) (the &ldquo;Registration Statement&rdquo;). The
Company has filed with the U.S. Securities and Exchange Commission a prospectus supplement dated February 7, 2023, together with an accompanying
prospectus dated September 17, 2021, relating to the offer and sale of the common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The net proceeds from the offer and sale of the
common shares is approximately $234.2 million, after deducting the underwriting discounts and commimssions and estimated offering expenses
payable by the Company. The Company intends to use the net proceeds from the offer and sale of the common shares to its ongoing business
activities and development of its pipeline and for other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report on Form 6-K (other than Exhibit 99.1),
including Exhibits 1.1, 5.1, 8.1, 8.2, 8.3, 23.1, 23.2, 23.3 and 23.4, shall be deemed to be incorporated by reference into the registration
statement on Form F-3 (Registration No. 333-259613) of CureVac N.V. and to be a part thereof from the date on which this report is filed,
to the extent not superseded by documents or reports subsequently filed.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CUREVAC N.V.</B></FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 10, 2023</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Franz-Werner Haas, LLD, LLM&#9;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Franz-Werner&nbsp;Haas</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.8in; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex1-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex1-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated February 7, 2023, between CureVac N.V. and Goldman Sachs &amp; Co. LLC, Jefferies LLC and SVB Securities LLC, as representatives of the several underwriters</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of NautaDutilh N.V., Dutch counsel of CureVac </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex8-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex8-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of NautaDutilh N.V., Dutch counsel of CureVac, as to Dutch tax matters</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex8-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex8-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of FALK GmbH &amp; Co KG, as to German tax matters</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex8-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex8-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Davis Polk &amp; Wardwell LLP, as to U.S. tax matters</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of NautaDutilh N.V. (included in Exhibit 5.1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex8-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex8-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of NautaDutilh N.V. (included in Exhibit 8.1)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex8-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex8-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of FALK GmbH &amp; Co KG (included in Exhibit 8.2)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex8-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex8-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Davis Polk &amp; Wardwell LLP (included in Exhibit 8.3)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><A HREF="tm236242d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD><A HREF="tm236242d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated February 10, 2023</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm236242d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1<I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CureVac N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Dutch company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">27,027,028 Common Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February 7, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CureVac N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Dutch company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">27,027,028 Common Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February 7, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-indent: -58.3pt">Goldman Sachs &amp; Co. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-indent: -58.3pt">Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-indent: -58.3pt">SVB Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">as Representatives of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">c/o Goldman Sachs &amp; Co. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">200 West Street<BR>
New York, New York 10282</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Jefferies LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">520 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o SVB Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1301 Avenue of the Americas, 12<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">CureVac N.V., a Dutch public
company with limited liability (<I>naamloze vennootschap</I>) (the &ldquo;Company&rdquo;) confirms its agreement with Goldman Sachs &amp;
Co. LLC (&ldquo;Goldman Sachs&rdquo;), Jefferies LLC (&ldquo;Jefferies&rdquo;), SVB Securities LLC (&ldquo;SVB Securities&rdquo;), and
each of the other Underwriters named in Schedule A hereto (collectively, the &ldquo;Underwriters,&rdquo; which term shall also include
any underwriter substituted as hereinafter provided in Section&nbsp;10 hereof), for whom Goldman Sachs, Jefferies and SVB Securities are
acting as representatives (in such capacity, collectively, the &ldquo;Representatives&rdquo;), with respect to (i) the sale by the Company
and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of common shares, par value &euro;0.12
per share, of the Company (&ldquo;Common Shares&rdquo;) set forth in Schedules&nbsp;A and B hereto and (ii) the grant by the Company to
the Underwriters, acting severally and not jointly, of the option described in Section&nbsp;2(b) hereof to purchase all or any part of
4,054,054 additional Common Shares. The aforesaid 27,027,028 Common Shares (the &ldquo;Initial Securities&rdquo;) to be purchased by the
Underwriters and all or any part of the 4,054,054 Common Shares subject to the option described in Section 2(b) hereof (the &ldquo;Option
Securities&rdquo;) are herein called, collectively, the &ldquo;Securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The Company understands that
the Underwriters propose to make a public offering of the Securities as soon as the Representative deems advisable after this Agreement
has been executed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The Company has prepared and
filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) an automatic shelf registration statement on Form&nbsp;F-3
(No. 333-259613) covering the public offering and sale of certain securities, including the Securities, under the Securities Act of 1933,
as amended (the &ldquo;1933 Act&rdquo;), and the rules and regulations promulgated thereunder (the &ldquo;1933 Act Regulations&rdquo;),
which automatic shelf registration statement became effective under Rule 462(e) under the 1933 Act Regulations (&ldquo;Rule 462(e)&rdquo;).
Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto to
such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference
therein at such time pursuant to Item 12 of Form F-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of
such time pursuant to Rule 430B under the 1933 Act Regulations (&ldquo;Rule 430B&rdquo;), is referred to herein as the &ldquo;Registration
Statement;&rdquo; <I>provided, however,</I> that the &ldquo;Registration Statement&rdquo; without reference to a time means such registration
statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time
shall be considered the &ldquo;new effective date&rdquo; of such registration statement with respect to the Securities within the meaning
of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated
by reference therein at such time pursuant to Item 12 of Form F-3 under the 1933 Act and the documents otherwise deemed to be a part thereof
as of such time pursuant to the Rule 430B. Each preliminary prospectus used in connection with the offering of the Securities, including
the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form F-3 under the 1933 Act, are collectively
referred to herein as a &ldquo;preliminary prospectus.&rdquo; Promptly after execution and delivery of this Agreement, the Company will
prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations
(&ldquo;Rule 424(b)&rdquo;). The final prospectus, in the form first furnished or made available to the Underwriters for use in connection
with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to
Item 6 of Form F-3 under the 1933 Act, are collectively referred to herein as the &ldquo;Prospectus.&rdquo; For purposes of this Agreement,
all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the
foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval
system (or any successor system) (&ldquo;EDGAR&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Applicable
Time&rdquo; means 6:00 P.M., New York City time, on February 7, 2023 or such other time as agreed by the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;General Disclosure
Package&rdquo; means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary
prospectus that is distributed to investors prior to the Applicable Time and the information included on Schedule B-1 hereto, all considered
together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Issuer Free
Writing Prospectus&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the 1933 Act Regulations (&ldquo;Rule
433&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the 1933 Act Regulations
(&ldquo;Rule 405&rdquo;)) relating to the Securities that is (i) required to be filed with the Commission by the Company, (ii) a &ldquo;road
show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission,
or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of
the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if
not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Issuer General
Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors,
as evidenced by its being specified in Schedule B-2 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Issuer Limited
Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Testing-the-Waters
Communication&rdquo; means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of or Rule
163B under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Written Testing-the-Waters
Communication&rdquo; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the
1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All references in this Agreement
to financial statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo;
(or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include
all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration
Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and
all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus
shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (collectively, the &ldquo;1934 Act&rdquo;), incorporated or deemed to be incorporated by reference in the Registration
Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof,
the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter,
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(i) <U>Registration
Statement and Prospectuses</U>. The Company meets the requirements for use of Form F-3 under the 1933 Act. The Registration Statement
is an &ldquo;automatic shelf registration statement&rdquo; (as defined in Rule 405) and the Securities have been and remain eligible for
registration by the Company on such automatic shelf registration statement. Each of the Registration Statement and any post-effective
amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or
any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the
Company&rsquo;s knowledge, contemplated. The Company has complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">Each of the Registration
Statement and any post-effective amendment thereto, at the time of its effectiveness, each deemed effective date with respect to the Underwriters
pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, the Applicable Time, the Closing Time and any Date of Delivery, complied and
will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus,
the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each case, at the Applicable
Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act
Regulations and each preliminary prospectus and the Prospectus delivered to the Underwriters for use in connection with this offering
was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">The documents incorporated
or deemed to be incorporated by reference in the Registration Statement and the Prospectus, when they became effective or at the time
they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934
Act and the rules and regulations of the Commission under the 1934 Act (the &ldquo;1934 Act Regulations&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ii) <U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time, on the date hereof, at the Closing
Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. At the Applicable
Time and any Date of Delivery, none of (A) the General Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus,
when considered together with the General Disclosure Package and (C) any individual Written Testing-the-Waters Communication, when considered
together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits
or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto, as of its issue date, at the time of any
filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include
an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated
by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement
became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together
with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not
and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">The representations
and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto),
the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with
written information furnished to the Company by any Underwriter through the Representative expressly for use therein. For purposes of
this Agreement, the only information so furnished shall be the information in the tenth, eleven and twelfth paragraphs under the caption
 &ldquo;Underwriting&rdquo; (collectively, the &ldquo;Underwriter Information&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(iii) <U>Issuer
Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration
Statement or the Prospectus, including any document incorporated by reference therein and any preliminary or other prospectus deemed to
be a part thereof that has not been superseded or modified. Any offer that is a written communication relating to the Securities made
prior to the initial filing of the Registration Statement by the Company or any person acting on its behalf (within the meaning, for this
paragraph only, of Rule 163(c) of the 1933 Act Regulations) has been filed with the Commission in accordance with the exemption provided
by Rule 163 under the 1933 Act Regulations (&ldquo;Rule 163&rdquo;) and otherwise complied with the requirements of Rule 163, including
without limitation the legending requirement, to qualify such offer for the exemption from Section 5(c) of the 1933 Act provided by Rule
163.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(iv) <U>Well-Known
Seasoned Issuer</U>. (A) At the original effectiveness of the Registration Statement, (B) at the time of the most recent amendment thereto
for the purposes of complying with Section 10(a)(3) of the 1933 Act (whether such amendment was by post-effective amendment, incorporated
report filed pursuant to Section 13 or 15(d) of the 1934 Act or form of prospectus), (C) at the time the Company or any person acting
on its behalf (within the meaning, for this clause only, of Rule 163(c) under the 1933 Act) made any offer relating to the Securities
in reliance on the exemption of Rule 163 under the 1933 Act, and (D) as of the Applicable Time, the Company was and is a &ldquo;well-known
seasoned issuer&rdquo; (as defined in Rule 405).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(v) <U>Testing-the-Waters
Materials</U>. The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with
the consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the 1933
Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B) has not authorized anyone
other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has been
authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters
Communications other than those listed on Schedule D hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(vi) <U>Company
Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of
the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo;
as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that
the Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(vii) <U>Independent
Accountants</U>. The accountants who certified the financial statements and supporting schedules included in the Registration
Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the
1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(viii) <U>Financial
Statements</U>. The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of
each of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders&rsquo; equity
and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared
in conformity with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards
Board applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in accordance with
IFRS the information required to be stated therein in all material respects. The selected financial data and the summary financial information
included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus present fairly
in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial
statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required
to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the
1933 Act, the 1933 Act Regulations, the 1934 Act or the 1934 Act Regulations. The interactive data in eXtensible Business Reporting Language
included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents
the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ix) <U>No Material
Adverse Change in Business</U>. Except as otherwise stated therein, since the respective dates as of which information is given in the
Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition,
financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one
enterprise, whether or not arising in the ordinary course of business (a &ldquo;Material Adverse Effect&rdquo;), (B)&nbsp;there have been
no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are
material with respect to the Company and its subsidiaries considered as one enterprise, and (C)&nbsp;except for regular dividends on the
Common Shares in amounts per share that are consistent with past practice, there has been no dividend or distribution of any kind declared,
paid or made by the Company on any class of its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(x) <U>Good Standing
of the Company</U>. The Company has been duly incorporated or otherwise organized and is validly existing as a corporation in good standing
(where such concept exists) under the laws of the jurisdiction of its organization and has corporate power and authority to own, lease
and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and
the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation
to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of
the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would
not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xi) <U>Good Standing
of Subsidiaries</U>. Each of the Company&rsquo;s subsidiaries (each, a &ldquo;Subsidiary&rdquo; and, collectively, the &ldquo;Subsidiaries&rdquo;)
has been duly incorporated or otherwise organized and is validly existing in good standing (where such concept exists) under the laws
of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties
and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason
of the ownership or leasing of property or the conduct of business, except where the failure to so qualify, to have such power or authority
or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement,
the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized
and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through subsidiaries, free and clear of
any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary
were issued in violation of the preemptive or similar rights of any security holder of such Subsidiary. The only Subsidiaries of the Company
are (A) the Subsidiaries listed on Exhibit 8.1 to the Company&rsquo;s most recent Annual Report on Form 20-F filed with the Commission,
as updated by the 6-K filed on November 17, 2022 and (B) certain other Subsidiaries which, considered in the aggregate as a single Subsidiary,
do not constitute a &ldquo;significant subsidiary&rdquo; as defined in Rule 1-02 of Regulation S-X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xii) <U>Capitalization</U>.
The authorized, issued and outstanding shares of capital stock of the Company is as set forth in the Registration Statement, the General
Disclosure Package and the Prospectus in the column entitled &ldquo;Actual&rdquo; under the caption &ldquo;Capitalization&rdquo; (except
for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred
to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to the exercise of convertible securities
or options referred to in the Registration Statement, the General Disclosure Package and the Prospectus). There are no authorized or outstanding
phantom equity, rights to receive shares, options, conversion rights, warrants, preemptive rights, rights of first refusal or other rights
to purchase, or equity or debt securities convertible into or exchangeable or exercisable for or that can be settled in, any share capital
of the Company or any of its subsidiaries other than those described in the Registration Statement, the General Disclosure Package and
the Prospectus. The issued shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and
non-assessable. None of the issued shares of capital stock of the Company were issued in violation of the preemptive or other similar
rights of any security holder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xiii) <U>Authorization
of Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xiv) <U>Authorization
and Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company have been duly authorized for issuance
and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement and a
deed of issue (each, a &ldquo;Deed of Issue&rdquo;), against payment of the consideration set forth herein, will be validly issued and
fully paid and non-assessable (meaning that the holders of the Securities will not by reason of merely being such a holder, be subject
to assessment or calls by the Company or its creditors for further payment on such Securities); and the issuance of the Securities is
not subject to the preemptive or other similar rights of any security holder of the Company, except as have been duly and validly waived.
The Securities conform in all material respects to all statements relating thereto contained in the Registration Statement, the General
Disclosure Package and the Prospectus and such description conforms in all material respects to the rights set forth in the instruments
defining the same. No holder of Securities will be subject to personal liability by reason of being such a holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xv) <U>Registration
Rights</U>. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant
to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other
than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus or that have
been waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xvi) <U>Absence
of Violations, Defaults and Conflicts</U>. Neither the Company nor any of its subsidiaries is (A) in violation of its articles of association
or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or condition
contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument
to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the properties
or assets of the Company or any subsidiary is subject (collectively, &ldquo;Agreements and Instruments&rdquo;), except for such defaults
that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation,
judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority,
body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations
(each, a &ldquo;Governmental Entity&rdquo;), except for such violations that would not, singly or in the aggregate, result in a Material
Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein
and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities
and the use of the proceeds from the sale of the Securities as described therein under the caption &ldquo;Use of Proceeds&rdquo;) and
compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will
not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment
Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets
of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment
Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such
action result in any violation of (i) the provisions of the articles of association or similar organizational document of the Company
or any of its subsidiaries or (ii) any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except
in the case of clause (ii) for any violation that would not, singly or in the aggregate, result in a Material Adverse Effect. As used
herein, a &ldquo;Repayment Event&rdquo; means any event or condition which gives the holder of any note, debenture or other evidence of
indebtedness (or any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all
or a portion of such indebtedness by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xvii) <U>Absence
of Labor Dispute</U>. Other than that which would not result in a Material Adverse Effect, (i) no labor dispute with the employees of
the Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent, and (ii) the Company is not aware of any
existing or imminent labor dispute with the employees of any of its or any subsidiary&rsquo;s principal suppliers, manufacturers, customers
or contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xviii) <U>Absence
of Proceedings</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, to the knowledge
of the Company, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending
or, to the knowledge of the Company, threatened, against the Company or any of its subsidiaries, which would reasonably be expected to
result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties
or assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations
hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or
of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the General
Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected
to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xix) <U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in the Registration Statement, the General Disclosure
Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xx) <U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree
of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with
the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement, except
such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of The Nasdaq Global
Select Market, state securities laws or the rules of Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxi) <U>Possession
of Licenses and Permits</U>. The Company and its subsidiaries possess such permits, licenses, approvals, consents and other authorizations
(collectively, &ldquo;Governmental Licenses&rdquo;) issued by the appropriate Governmental Entities necessary to conduct the business
now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect.
The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure
so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and
in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be
in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its
subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxii) <U>Title
to Property</U>. The Company and its subsidiaries have good and marketable title to all real property owned by them and good title to
all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions
or encumbrances of any kind except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus
or (B) do not, singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed
to be made of such property by the Company or any of its subsidiaries; and all of the leases and subleases material to the business of
the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries holds properties
described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the
Company nor any such subsidiary has any notice of any material claim of any sort that has been asserted by anyone (A) adverse to the rights
of the Company or any subsidiary under any of the leases or subleases mentioned above, or (B) affecting or questioning the rights of the
Company or such subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxiii) <U>Possession
of Intellectual Property</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or
where it would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;the Company and its subsidiaries own, possess
or have the right to use, or can acquire the right to use on reasonable terms, all patents, licenses, inventions, copyrights, know-how
(including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks,
service marks, trade names or other intellectual property (collectively, &ldquo;Intellectual Property&rdquo;) necessary to carry on the
business now operated by them and as currently proposed to be conducted as described in the Registration Statement, the General Disclosure
Package or the Prospectus, (B)&nbsp;to the knowledge of the Company, all Intellectual Property owned by or exclusively licensed to the
Company or its subsidiaries (such Intellectual Property, the &ldquo;Company Intellectual Property&rdquo;) has been duly and properly filed
and maintained, is free and clear of liens or security interests, and is in full force and effect, valid, subsisting and enforceable,
(C)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by any third party challenging
the validity, ownership, registrability, enforceability or scope of any Company Intellectual Property and the Company is unaware of any
facts which would form a reasonable basis for any such claim, (D) no third party, to the knowledge of the Company, is infringing, misappropriating
or otherwise violating any Company Intellectual Property and there is no pending or threatened action, suit, proceeding or claim by the
Company or any of its subsidiaries against a third party regarding the foregoing, (E)&nbsp;(1) neither the Company nor any of its subsidiaries
has received any written notice of nor, to the knowledge of the Company, has engaged in, any infringement, misappropriation or other violation
of any Intellectual Property of any third party, (2) there is no pending or, to the knowledge of the Company, threatened action, suit,
proceeding or claim regarding the subject matter of the foregoing, and (3) the Company and its subsidiaries are unaware of any facts which
would form a reasonable basis for any such claim, (F)&nbsp;to the knowledge of the Company, the parties prosecuting patent applications
within the Company Intellectual Property have complied with their duty of candor and disclosure to the USPTO or foreign patent offices,
as applicable, in connection with such applications and the Company is not aware of any facts required to be disclosed to the USPTO or
foreign patent offices that were not disclosed and which would preclude the grant of a patent in connection with any such patent application
or could form the basis of a finding of invalidity or unenforceability with respect to any patents that have issued with respect to such
patent applications, (G) each person who is or was an employee or contractor of the Company or any of its subsidiaries and who is or was
involved in the creation or development of any Company Intellectual Property for or on behalf of the Company has executed a valid agreement
containing an assignment or exclusive license to the Company or any of its subsidiaries of such person&rsquo;s rights in and to such Company
Intellectual Property, (H) the Company has taken reasonable steps in accordance with standard industry practice to maintain and protect
the confidentiality of the trade secrets and other confidential Intellectual Property used in connection with the business of the Company
and its subsidiaries and, to the knowledge of the Company, such confidential Intellectual Property has not been compromised or disclosed
to or accessed by any third party except pursuant to nondisclosure and confidentiality agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxiv) <U>Environmental
Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or where it would not,
singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company nor any of its subsidiaries is in violation of
any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, legally binding policy or rule of common law or
any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating
to pollution or protection of worker health and safety, the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened
release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing
materials or mold, but excluding the Company&rsquo;s or any of its subsidiaries&rsquo; products (collectively, &ldquo;Hazardous Materials&rdquo;)
or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
 &ldquo;Environmental Laws&rdquo;), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under
any applicable Environmental Laws and are each in compliance with their requirements, (C) there are no pending or threatened administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or
proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D) to the Company&rsquo;s knowledge,
there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an
action, suit or proceeding by any private party or Governmental Entity, against the Company or any of its subsidiaries relating to Hazardous
Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxv) <U>Accounting
Controls and Disclosure Controls.</U> Except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
the Company and each of its subsidiaries maintain a system of internal control over financial reporting (as defined under Rule 13-a15
and 15d-15 under the 1934 Act Regulations) and a system of internal accounting controls designed to provide reasonable assurances that
(A) transactions are executed in accordance with management&rsquo;s general or specific authorization; (B) transactions are recorded as
necessary to permit preparation of financial statements in conformity with IFRS and to maintain accountability for assets; (C) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (D) the recorded accountability for
assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General
Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance
with the Commission's rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure
Package and the Prospectus, since the end of the Company&rsquo;s most recent audited fiscal year, there has been (1) no material weakness
in the Company&rsquo;s internal control over financial reporting (whether or not remediated) and (2) no change in the Company&rsquo;s
internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely
affect, the Company&rsquo;s internal control over financial reporting. The Company and each of its subsidiaries maintain an effective
system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934 Act Regulations) that are designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms, and is accumulated and
communicated to the Company&rsquo;s management, including its principal executive officer or officers and principal financial officer
or officers, as appropriate, to allow timely decisions regarding disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxvi) <U>Compliance
with the Sarbanes-Oxley Act.</U> There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the
rules and regulations promulgated in connection therewith (the &ldquo;Sarbanes-Oxley Act&rdquo;), including Section 402 related to loans
and Section 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxvii) <U>Payment
of Taxes</U>. All United States federal income tax returns of the Company and its subsidiaries required by law to be filed have been filed
and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which
appeals have been or will be promptly taken and as to which adequate reserves have been provided in accordance with GAAP. The United States
federal income tax returns of the Company through the fiscal year ended December 31, 2021 have been settled and no assessment in connection
therewith has been made against the Company. The Company and its subsidiaries have filed all other tax returns that are required to have
been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would
not result in a Material Adverse Effect, and has paid all material taxes due pursuant to such returns or pursuant to any assessment received
by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves
have been established by the Company in accordance with IFRS. The charges, accruals and reserves on the books of the Company in respect
of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments
for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxviii) <U>Transfer
Taxes</U>. &#9;No stamp duty, stamp duty reserve, registration, issuance, transfer taxes or other similar documentary taxes, duties, fees
or charges (&ldquo;Transfer Taxes&rdquo;) are payable or required to be paid by or on behalf of the Underwriters in the Netherlands or
any political subdivision, authority or agency thereof or therein having power to tax in connection with (i) the execution, delivery and
performance of this Agreement, (ii) the issuance and delivery of the Securities in the manner contemplated by this Agreement and the Prospectus,
or (iii) the sale and delivery by the Underwriters of the Securities as contemplated herein and in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxix) <U>PFIC Status</U>.
Based on the current and anticipated value of its assets and the nature and composition of its income and assets, and subject to the qualifications
set forth in the Registration Statement, the General Disclosure Package and the Prospectus, the Company does not believe it was a &ldquo;passive
foreign investment company&rdquo; within the meaning of Section 1297 of the Code for the taxable year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxx) <U>Insurance</U>.
The Company and its subsidiaries carry or are entitled to the benefits of insurance, with reputable insurers, in such amounts and covering
such risks as is generally maintained by companies of established repute and of comparable size engaged in the same or similar business,
and all such insurance considered to be material for operating the Company&rsquo;s and its subsidiaries&rsquo; businesses is in full force
and effect. The Company has no reason to believe that it or any of its subsidiaries will not be able (A)&nbsp;to renew its existing insurance
coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate
to conduct its business as now conducted and at a cost that, in each case, would not reasonably be expected to result in a Material Adverse
Effect. Neither of the Company nor any of its subsidiaries has been denied any material insurance coverage which it has sought or for
which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxi) <U>Investment
Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated and the application
of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be
required, to register as an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxii) <U>Absence
of Manipulation</U>. Neither the Company nor, to the Company&rsquo;s knowledge, any affiliate of the Company has taken, nor will the Company
or any affiliate controlled by the Company take, directly or indirectly, any action which is designed, or would reasonably be expected,
to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxiii) <U>No Rights
of Immunity; Enforcement of Foreign Judgments</U>. Except as provided by laws or statutes generally applicable to transactions of the
type described in this Agreement, neither the Company nor any of its respective properties, assets or revenues has any right of immunity
under the laws of the Netherlands, New York or United States law, from any legal action, suit or proceeding, from the giving of any relief
in any such legal action, suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Dutch, New York or United States
federal court, from service of process, attachment upon or prior judgment, or attachment in aid of execution of judgment, or from execution
of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court,
with respect to its obligations, liabilities or any other matter under or arising out of or in connection with this Agreement. To the
extent that the Company or any of its respective properties, assets or revenues may have or may hereafter become entitled to any such
right of immunity in any such court in which proceedings may at any time be commenced, the Company waives or will waive such right to
the extent permitted by law and has consented to such relief and enforcement as provided in Section 17 of this Agreement. Any final judgment
for a fixed or determined sum of money rendered by any U.S. federal or New York state court located in the State of New York having jurisdiction
under its own laws in respect of any suit, action or proceeding against the Company based upon this Agreement would be declared enforceable
against the Company by the courts of the Netherlands, without reconsideration or reexamination of the merits, subject to the restrictions
described under the caption &ldquo;Enforcement of Judgments&rdquo; in the Registration Statement, the General Disclosure Package and the
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxiv) <U>Foreign
Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent,
employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly
or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules
and regulations thereunder (the &ldquo;FCPA&rdquo;), including, without limitation, making use of the mails or any means or instrumentality
of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or
other property, gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign official&rdquo; (as such
term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention
of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the
FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure,
continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxv) <U>Money
Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;Money Laundering Laws&rdquo;); and no action, suit
or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering
Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxvi) <U>OFAC</U>.
None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or
representative of the Company or any of its subsidiaries is an individual or entity (&ldquo;Person&rdquo;) currently the subject or target
of any officially released sanctions administered or enforced by the United States Government, including, without limitation, the U.S.
Department of the Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;OFAC&rdquo;), the United Nations Security Council (&ldquo;UNSC&rdquo;),
the European Union, His Majesty&rsquo;s Treasury (&ldquo;HMT&rdquo;), the Swiss Secretariat of Economic Affairs, or other relevant sanctions
authority (collectively, &ldquo;Sanctions&rdquo;), nor is the Company located, organized or resident in a country or territory that is
the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute
or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business
with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner
that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor,
investor or otherwise) of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxvii) <U>Lending
Relationship</U><I>. </I>Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company
(i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of any Underwriter and (ii)&nbsp;does
not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxviii) <U>Statistical
and Market-Related Data</U>. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package
or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate
and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xxxix) <U>Cybersecurity</U>.
Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or where it would not, singly or
in the aggregate, result in a Material Adverse Effect, (A) to the knowledge of the Company, there has been no security breach or incident,
unauthorized access or disclosure, or other compromise of or relating to the Company&rsquo;s or its subsidiaries&rsquo; information technology
and computer systems, networks, hardware, software, confidential data and databases (including the confidential data and information of
their respective customers, employees, suppliers, vendors and any third-party confidential data maintained, processed or stored by the
Company and its subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its subsidiaries), equipment
or technology (collectively, &ldquo;IT Systems and Data&rdquo;), (B) neither the Company nor its subsidiaries have been notified in writing,
or have any knowledge, of any event or condition that is reasonably likely to result in any security breach or incident, unauthorized
access or disclosure or other compromise to their IT Systems and Data, (C) the Company and its subsidiaries have implemented commercially
reasonable controls, policies, procedures, and technological safeguards to maintain and protect the integrity, continuous operation, redundancy
and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory
standards and (D) to the knowledge of the Company,&nbsp;the Company and its subsidiaries are presently in compliance with all applicable
laws or statutes and all applicable material judgments, orders, rules and regulations of any court, arbitrator or governmental or regulatory
authority and contractual obligations relating to the privacy and security of their IT Systems and Data and to the protection of such
IT Systems and Data from unauthorized use, access, misappropriation or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xl) <U>Regulatory
Compliance</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, each of the Company
and its subsidiaries: (i) has operated and currently operates its business in compliance in all material respects with applicable provisions
of the Health Care Laws (as defined below) of the Food and Drug Administration (&ldquo;FDA&rdquo;), the Department of Health and Human
Services (&ldquo;HHS&rdquo;) and any comparable foreign or other regulatory authority to which they are subject (collectively, the &ldquo;Applicable
Regulatory Authorities&rdquo;) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
storage, import, export or disposal of any of the Company&rsquo;s or its subsidiaries&rsquo; product candidates or any product manufactured
or distributed by the Company and its subsidiaries; (ii) has not received any FDA Form 483, written notice of adverse finding, warning
letter, untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority
alleging or asserting non-compliance with (A) any Health Care Laws or (B) or any licenses, certificates, approvals, clearances, exemptions,
authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (&ldquo;Regulatory Authorizations&rdquo;);
(iii) possesses all Regulatory Authorizations required to conduct its business as currently conducted, except where the failure to possess
the same would not, individually or in the aggregate, have a Material Adverse Effect, and such Regulatory Authorizations are valid and
in full force and effect and neither the Company nor any of its subsidiaries are in violation, in any material respect, of any term of
any such Regulatory Authorizations; (iv) has not received written notice of any claim, action, suit, audit, survey, proceeding, hearing,
enforcement, investigation, arbitration or other action from the Applicable Regulatory Authorities or any other third party alleging that
any product of the Company is in material violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the
Applicable Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation
or proceeding; (v) has not received written notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to
take action to limit, suspend, modify or revoke any material Regulatory Authorizations and has no knowledge that any of the Applicable
Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory
Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii)
is not a party to or have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements,
monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable
Regulatory Authority; and (viii) along with its employees, officers and directors has not been excluded, suspended or debarred from participation
in any government health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension or exclusion.
The term &ldquo;Health Care Laws&rdquo; means Title XVIII of the Social Security Act, 42 U.S.C. &sect;&sect; 1395-1395hhh (the Medicare
statute); Title XIX of the Social Security Act, 42 U.S.C. &sect;&sect; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute,
42 U.S.C. &sect; 1320a-7b(b); the civil False Claims Act, 31 U.S.C. &sect;&sect; 3729 et seq.; the criminal False Claims Act, 42 U.S.C.
1320a-7b(a); any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1001,
1035, 1347 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996,
42 U.S.C. &sect;&sect; 1320d et seq., (&ldquo;HIPAA&rdquo;); the Civil Monetary Penalties Law, 42 U.S.C. &sect;&sect; 1320a-7a and 1320a-7b;
the Physician Payments Sunshine Act, 42 U.S.C. &sect; 1320a-7h; the Exclusion Laws, 42 U.S.C. &sect; 1320a-7; HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &sect;&sect; 17921 et seq.; the Federal Food, Drug, and
Cosmetic Act, 21 U.S.C. &sect;&sect; 301 et seq.; the Public Health Service Act, 42 U.S.C. &sect;&sect; 201 et seq.; each as amended,
and the regulations promulgated pursuant to such laws; and any similar foreign, federal, state and local laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xli) <U>Manufacturing
and Suppliers</U>. To the Company&rsquo;s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance
in with all applicable statutes, rules, regulations and policies of the Applicable Regulatory Authorities, including, without limitation,
the Health Care Laws, except for such non-compliance that would not, singly or in the aggregate reasonably be expected to result in a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xlii) <U>Studies,
Tests and Trials</U>. None of the Company&rsquo;s product candidates have received marketing approval or licensure from any Applicable
Regulatory Authority. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, all clinical
and pre-clinical studies and trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company or its
subsidiaries, or in which the Company or its subsidiaries has participated, with respect to the Company&rsquo;s product candidates, including
any such studies and trials that are described in the Registration Statement, General Disclosure Package and the Prospectus, or the results
of which are referred to in the Registration Statement, General Disclosure Package and the Prospectus, as applicable (collectively, &ldquo;Company
Trials&rdquo;), were, and if still pending are, to the Company's knowledge, being conducted in all material respects in accordance with
the Health Care Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices, and with standard
medical and scientific research procedures and any applicable rules, regulations and policies of the jurisdiction in which such trials
and studies are being conducted; the descriptions in the Registration Statement, General Disclosure Package and the Prospectus of the
results of any Company Trials are accurate and complete descriptions in all material respects and fairly present the data derived therefrom;
the Company has no knowledge of any other studies or trials not described in the Registration Statement, General Disclosure Package and
the Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the Registration
Statement, General Disclosure Package and the Prospectus; the Company and each of its subsidiaries have not received, any written notices,
correspondence or other communications from the Applicable Regulatory Authorities or any other governmental entity requiring or threatening
the termination, material modification or suspension of Company Trials that are described in the Registration Statement, the General Disclosure
Package and the Prospectus or the results of which are referred to in the Registration Statement, the General Disclosure Package and the
Prospectus, other than ordinary course communications with respect to modifications in connection with the design and implementation of
such studies or trials, and, to the Company&rsquo;s knowledge, there are no reasonable grounds for the same. No investigational new drug
application or comparable submission filed by or on behalf of the Company or any of its subsidiaries has been terminated or suspended
by the FDA or any other Applicable Regulatory Authority. The Company has obtained (or caused to be obtained) informed consent by or on
behalf of each human subject who participated in a Company Trial. In using or disclosing patient information received by the Company or
any of its subsidiaries in connection with a Company Trial, the Company or such subsidiary has complied in all material respects with
all applicable laws and regulatory rules or requirements, including, without limitation, HIPAA and the rules and regulations thereunder.
To the Company&rsquo;s knowledge, none of the Company Trials involved any investigator who has been disqualified as a clinical investigator
or has been found by the FDA to have engaged in scientific misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xliii) <U>Maintenance
of Rating</U>. At the date of this Agreement, neither the Company nor its subsidiaries have any debt securities or preferred shares that
are rated by any &ldquo;nationally recognized statistical rating agency&rdquo; (as defined in Section 3(a)(62) of the 1934 Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xliv) <U>Dividend
Restrictions</U>. Other than as prohibited or restricted by law, no subsidiary of the Company is prohibited or restricted, directly or
indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&rsquo;s equity
securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under
any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary.
No approvals are currently required under Dutch law in order for the Company to pay dividends or other distributions declared by the Company
to the holders of Common Shares subject to the approvals described under the caption &ldquo;Dividends&rdquo; in the Registration Statement,
the General Disclosure Package and the Prospectus. Under current Dutch laws and regulations, any amount payable with respect to the Common
Shares upon liquidation of the Company or upon redemption thereof and dividends and other distributions declared and payable on the share
capital of the Company may be paid by the Company in United States dollars and freely transferred out the Netherlands, subject to the
restrictions described under the caption &ldquo;Exchange Controls&rdquo; in the Registration Statement, the General Disclosure Package
and the Prospectus. Except as otherwise described in the Registration Statement, the Disclosure Package and the Prospectus, all dividends
and other distributions paid by the Company in respect of the common shares will not be subject to withholding or deduction of any taxes
imposed, levied, withheld or assessed by the Netherlands or any political subdivision or taxing authority thereof or therein and may be
made without the necessity of obtaining any governmental authorization in Netherlands or any political subdivision or taxing authority
thereof or therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xlv) <U>Valid Choice
of Law</U>. The Dutch courts recognize the choice of the laws of the State of New York to govern the obligations of the Company under
this Agreement, and accordingly the Dutch courts will determine the enforceability of those obligations by reference to the laws of the
State of New York. The agreement conferring jurisdiction in this Agreement will be recognized under Dutch law, and given effect to by
the Dutch courts. The Company has the corporate power to enter into this Agreement and to perform its obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xlvi) <U>Indemnification
and Contribution</U>. The indemnification and contribution provisions set forth in Section 6 hereof do not contravene the laws or public
policies of the Netherlands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(xlvii) Legality;
Legal Action. The legality, validity, enforceability or admissibility into evidence of any of the Registration Statement, the General
Disclosure Package, the Prospectus, this Agreement or the Securities in the Netherlands is not dependent upon such document being submitted
into, filed or recorded with any court or other authority in the Netherlands on or before the date hereof or that any documentation taxes
(commonly referred to as stamp duties), imposition or charge be paid in the Netherlands on or in respect of any such document, notwithstanding
that court fees may be due in respect of or in connection with the enforcement by legal proceedings. Any holder of the Securities and
each Underwriter are each entitled to sue as plaintiff in the court of the jurisdiction of formation and domicile of the Company (&ldquo;Non-Specified
Courts&rdquo;) for the enforcement of any Related Judgement (as defined in Section 17 herein), as to which the jurisdiction of the Specified
Courts (as defined in Section 17 herein) is non-exclusive, and such access to such Non-Specified Courts will not be subject to any conditions
which are not applicable to residents of such jurisdiction or a company incorporated in such jurisdiction except that plaintiffs not residing
in the Netherlands may be required to guarantee payment of a possible order for payment of costs or damages at the request of the defendant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Officer&rsquo;s Certificates. </I>Any certificate signed by any officer of the Company or any of its subsidiaries delivered
to the Representative or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter
as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale and Delivery to Underwriters; Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly,
agrees to purchase from the Company, at the price per share set forth in Schedule A, that number of Initial Securities set forth in Schedule
A opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated
to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such adjustments among the Underwriters as the
Representative in its sole discretion shall make to eliminate any sales or purchases of fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Option Securities</I>. In addition, on the basis of the representations and warranties herein contained and subject to the terms
and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to
an additional 4,054,054 Common Shares at the price per share set forth in Schedule A, less an amount per share equal to any dividends
or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby
granted may be exercised for 30&nbsp;days after the date hereof and may be exercised in whole or in part at any time from time to time
upon notice by the Representative to the Company setting forth the number of Option Securities as to which the several Underwriters are
then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery
(a &ldquo;Date of Delivery&rdquo;) shall be determined by the Representative, but shall not be later than seven full business days after
the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option
Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities
then being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the
total number of Initial Securities, subject, in each case, to such adjustments as the Representatives in their sole discretion shall make
to eliminate any sales or purchases of fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Payment</I>. Payment of the purchase price for, and delivery of, the Initial Securities shall be made at the offices of Latham
 &amp; Watkins LLP, 1271 Avenue of the Americas, New York, New York 10020, or at such other place as shall be agreed upon by the Representative
and the Company, at 9:00&nbsp;A.M. (New York City time) on the second (third, if the pricing occurs after 4:30 P.M. (New York City time)
on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such
other time not later than ten business days after such date as shall be agreed upon by the Representative and the Company (such time and
date of payment and delivery being herein called &ldquo;Closing Time&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, in the event
that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of, such Option
Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Representative and the
Company, on each Date of Delivery as specified in the notice from the Representative to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Payment shall be made to the
Company by wire transfer of immediately available funds to a bank account designated by the Company against delivery to the Representative
for the respective accounts of the Underwriters of the Securities to be purchased by them, or pursuant to other arrangements as shall
be agreed upon by the Company and the Representative prior to the Closing Time. It is understood that each Underwriter has authorized
the Representative, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities
and the Option Securities, if any, which it has agreed to purchase. Goldman Sachs, individually and not as representative of the Underwriters,
may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to
be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may
be, but such payment shall not relieve such Underwriter from its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Delivery of the Initial Securities
and any Option Securities shall be made through the facilities of The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Covenants of the Company</U>. The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section 3(b), will comply with the
requirements of Rule 430B, and will notify the Representative as soon as practicable, and confirm the notice in writing, (i) when any
post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have
been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment
to the Registration Statement or any amendment or supplement to the Prospectus or for additional information, (iv)&nbsp;of the issuance
by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any
order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the
Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or
of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes
the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities. The Company will effect
all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)),
and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule
424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company
will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued,
to obtain the lifting thereof at the earliest possible moment. The Company shall pay the required Commission filing fees relating to the
Securities within the time required by Rule 456(b)(1)(i) under the 1933 Act Regulations without regard to the proviso therein and otherwise
in accordance with Rules 456(b) and 457(r) under the 1933 Act Regulations (including, if applicable, by updating the &ldquo;Calculation
of Registration Fee&rdquo; table in accordance with Rule 456(b)(1)(ii) either in a post-effective amendment to the Registration Statement
or on the cover page of a prospectus filed pursuant to Rule 424(b)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934
Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement
and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the
Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&ldquo;Rule 172&rdquo;), would be) required
by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result
of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in
order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package
or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the
circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the
General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933
Act Regulations, the Company will promptly (A) give the Representative notice of such event, (B) prepare any amendment or supplement as
may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus
comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies
of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; <I>provided</I> that the Company
shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object.
The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably
request. The Company has given the Representative notice of any filings made pursuant to the 1934 Act or 1934 Act Regulations within 48
hours prior to the Applicable Time; the Company will give the Representative notice of its intention to make any such filing from the
Applicable Time to the Closing Time and will furnish the Representative with copies of any such documents a reasonable amount of time
prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for
the Underwriters shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Representative and counsel for the
Underwriters, without charge, copies of the Registration Statement as originally filed and each amendment thereto (including exhibits
filed therewith or incorporated by reference therein and documents incorporated or deemed to be incorporated by reference therein) and
copies of all consents and certificates of experts. The copies of the Registration Statement and each amendment thereto furnished to the
Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to
the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary
prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted
by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities
is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the
Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto
furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Blue Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify
the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign)
as the Representative may reasonably designate and to maintain such qualifications in effect so long as required to complete the distribution
of the Securities; <I>provided</I>, <I>however,</I> that the Company shall not be obligated to file any general consent to service of
process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to
subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally
available to its security holders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters
the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified
in the Registration Statement, the General Disclosure Package and the Prospectus under &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Listing</I>. The Company will use its reasonable best efforts to maintain its listing of the Common Shares (including the Option
Securities) on The Nasdaq Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Restriction on Sale of Securities</I>. During a period of 60 days from the date of the Prospectus, the Company will not, without
the prior written consent of the Representative, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or
dispose of any capital stock of the Company, or any securities convertible into or exercisable or exchangeable for capital stock of the
Company or file any registration statement under the 1933 Act with respect to any of the foregoing or (ii) enter into any swap or any
other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership
of the Common Shares, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common
Shares or other securities, in cash or otherwise. The foregoing sentence shall not apply to: (A) the Securities to be sold hereunder,
(B) any Common Shares issued or delivered by the Company upon the exercise of an option or warrant or the conversion of a security outstanding
on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C) any Common Shares
issued or delivered or options to purchase Common Shares granted pursuant to existing employee benefit plans of the Company or CureVac
AG referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (D) any Common Shares issued pursuant
to any non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure
Package and the Prospectus, (E) the filing by the Company of any registration statement on Form S-8 or a successor form thereto with respect
to the registration of securities to be offered under any employee benefit or equity incentive plan referred to in the Registration Statement,
the General Disclosure Package and the Prospectus, and (F) Common Shares or other securities issued in connection with a transaction that
includes a commercial relationship (including strategic alliances, commercial lending relationships, joint ventures, licensing agreements,
collaboration agreements and strategic acquisitions), <I>provided</I> that (i) the aggregate number of shares issued pursuant to this
clause (F) shall not exceed 10.0% of the total number of outstanding Common Shares immediately following the issuance and sale of the
Common Shares and (ii) the recipient of any such Common Shares or securities issued pursuant to this clause (F) during the 60-day restricted
period shall enter into an agreement substantially in the form of Exhibit D hereto. For the avoidance of doubt the restrictions in this
section 3(i) shall not apply to the Registration Rights Agreement entered into in connection with the initial public offering of the Company,
as described in the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>[Reserved</I>.<I>]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Reporting Requirements</I>.
The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would
be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934
Act within the time periods required by the 1934 Act and 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Issuer
Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written consent of the Representative, it will not
make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule 433; <I>provided</I> that the Representative will be deemed to have consented to the Issuer Free Writing Prospectuses
listed on Schedule B-2 hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i)
that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free
writing prospectus consented to, or deemed consented to, by the Representative as an &ldquo;issuer free writing prospectus,&rdquo; as
defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including
timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would
conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would
include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative
and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict,
untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(m) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>[Reserved.]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Testing-the-Waters
Materials.</I> If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event
or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material
fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement,
at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Tax
Indemnity</I>. The Company will indemnify and hold harmless the Underwriters against any Transfer Taxes, including any interest and penalties,
which are required to be paid on (i) the execution, delivery and performance of this Agreement, or (ii) the issuance and delivery of the
Securities in the manner contemplated by this Agreement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Withholding Taxes. </I> The Company agrees that all amounts payable hereunder shall be paid free and clear of, and without any deduction
or withholding for or on account of, any current or future taxes, levies, imposts, duties, charges or other deductions or withholdings
levied in any jurisdiction from or through which payment is made on behalf of the Company, unless such deduction or withholding is required
by applicable law, in which event the Company will pay additional amounts so that the persons entitled to such payments will receive the
amount that such persons would otherwise have received had such deduction or withholding not been required; <I>provided</I>, <I>however,</I>
that, upon request, each such person shall cooperate reasonably with the Company to reduce or eliminate amounts required to be so deducted
or withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of their obligations under
this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and
exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of copies
of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and
any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance
and delivery of the Securities to the Underwriters, including any stock or other Transfer Taxes, (iv)&nbsp;the fees and disbursements
of the Company&rsquo;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in
accordance with the provisions of Section&nbsp;3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel
for the Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey and any supplement thereto,
(vi) the fees and expenses of any transfer agent or registrar for the Securities, (vii) the costs and expenses of the Company relating
to investor presentations on any &ldquo;road show&rdquo; undertaken in connection with the marketing of the Securities, including without
limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged by
the Company in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company
and any such consultants (<I>provided</I> that the travel, lodging and any car travel expenses of representatives of the Underwriters
shall be paid for by the Underwriters), and fifty percent (50%) of the cost of any aircraft chartered in connection with the road show
(with the Underwriters agreeing to pay for the other fifty percent (50%) of the cost of the aircraft, as well as any other travel and
lodging expenses of the Underwriters in connection with the road show), (viii) the filing fees incident to, and the reasonable fees and
disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities <I>provided
</I>that the amount payable by the Company pursuant to clause (v) above and this clause (viii), excluding requisite filing fees, shall
not exceed $35,000, (ix) the fees and expenses incurred in connection with the listing of the Securities on The Nasdaq Global Select
Market and (x) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or
contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a
breach of the representation contained in the third and fourth sentences of Section 1(a)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination of Agreement</I>. If this Agreement is terminated by the Representative in accordance with the provisions of Section&nbsp;5,
Section&nbsp;9(a)(i) or (iii), or Section 10 hereof, the Company shall reimburse the non-defaulting Underwriters for all of their reasonable,
documented out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Underwriters, <I>provided</I>, <I>however,</I>
that if this Agreement is terminated pursuant to Section 10, the Company shall not be required to reimburse any costs, expenses, fees
and disbursements whatsoever of the defaulting Underwriters that have failed to purchase the Securities that they have agreed to purchase
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions of Underwriters&rsquo; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any
of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations
hereunder, and to the following further conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Effectiveness of Registration Statement</I>. The Registration Statement, including any Rule 462(b) Registration Statement, has
become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge,
contemplated; and the Company has complied with each request (if any) from the Commission for additional information. The Company shall
have paid the required Commission filing fees relating to the Securities within the time period required by Rule 456(b)(1)(i) under the
1933 Act Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the 1933 Act
Regulations and, if applicable, shall have updated the &ldquo;Calculation of Registration Fee&rdquo; table in accordance with Rule 456(b)(1)(ii)
either in a post-effective amendment to the Registration Statement or on the cover page of a prospectus filed pursuant to Rule 424(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion of Counsel for Company</I>. At the Closing Time, the Representative shall have received the favorable opinion, dated
the Closing Time, of Davis Polk &amp; Wardwell LLP, counsel for the Company, in form and substance satisfactory to counsel for the Underwriters,
together with signed or reproduced copies of such letter for each of the other Underwriters to the effect set forth in Exhibit A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion of Intellectual Property Counsel for the Company</I>. At the Closing Time, the Representative shall have received the
favorable opinion, dated the Closing Time, of each of ParkerHighlander PLLC and Graf von Stosch Patentanwaltsgesellschaft mbH, intellectual
property counsel for the Company, in form and substance satisfactory to counsel for the Underwriters, together with signed or reproduced
copies of such letter for each of the other Underwriters to the effect set forth in Exhibits B-1 and B-2 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion of Dutch Counsel for the Company.</I> At the Closing Time, the Representative shall have received the favorable opinion,
dated the Closing Time, of NautaDutilh N.V., Dutch counsel for the Company, in form and substance satisfactory to counsel for the Underwriters,
together with signed or reproduced copies of such letter for each of the other Underwriters to the effect set forth in Exhibit C hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Opinion of Counsel for Underwriters</I>. At the Closing Time, the Representative shall have received the favorable opinion,
dated the Closing Time, of Latham &amp; Watkins LLP, counsel for the Underwriters, in such form and substance as satisfactory to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Officers&rsquo; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective
dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse
change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries
considered as one enterprise, whether or not arising in the ordinary course of business, and the Representative shall have received a
certificate of the Chief Executive Officer or the President of the Company and of the chief financial or chief accounting officer of the
Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii)&nbsp;the representations
and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly made at and as
of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its part to be performed
or satisfied at or prior to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under
the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued
and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Chief Financial Officer&rsquo;s
Certificate.</I> At the time of the execution of this Agreement and at the Closing Time, the Representative shall have received a certificate
of the Chief Financial Officer of the Company, dated the date of this Agreement or the Closing Time, as applicable, reasonably satisfactory
to the Representative, as to the accuracy of certain data contained in the Registration Statement, the General Disclosure Package and
the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Accountant&rsquo;s
Comfort Letter</I>. At the time of the execution of this Agreement, the Representative shall have received from Ernst &amp; Young GmbH
Wirtschaftspr&uuml;fungsgesellschaft a letter, dated such date, in form and substance satisfactory to the Representative, together with
signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily
included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain financial
information contained in the Registration Statement, the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Bring-down Comfort Letter</I>.
At the Closing Time, the Representative shall have received from Ernst &amp; Young GmbH Wirtschaftspr&uuml;fungsgesellschaft a letter,
dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (i)
of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Approval
of Listing</I>. At the Closing Time, the Securities shall have been approved for listing on The Nasdaq Global Select Market, subject
only to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No Objection</I>. FINRA
has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements
relating to the offering of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Lock-up Agreements</I>.
At the date of this Agreement, the Representative shall have received an agreement substantially in the form of Exhibit&nbsp;D hereto
signed by the persons listed on Schedule C hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Conditions to Purchase
of Option Securities</I>. In the event that the Underwriters exercise their option provided in Section&nbsp;2(b) hereof to purchase all
or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any
certificates furnished by the Company and any of its subsidiaries hereunder shall be true and correct as of each Date of Delivery and,
at the relevant Date of Delivery, the Representative shall have received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. A certificate, dated such Date of Delivery, of the President or a Vice President of the Company and of the chief financial
or chief accounting officer of the Company confirming that the certificates delivered at the Closing Time pursuant to Section&nbsp;5(f)
hereof remains true and correct as of such Date of Delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Chief
Financial Officer&rsquo;s Certificate</U>. A certificate, dated such Date of Delivery, of the Chief Financial Officer of the Company confirming
that the certificate delivered at the Closing Time pursuant to Section 5(g) hereof remains true and correct as of such Date of Delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Counsel for Company</U>. If requested by the Representative, the favorable opinion of Davis Polk &amp; Wardwell LLP, counsel for the
Company, together with the favorable opinion of each of ParkerHighlander PLLC and Graf von Stosch Patentanwaltsgesellschaft mbH, intellectual
property counsel for the Company, and NautaDutilh N.V., Dutch counsel for the Company, each in form and substance satisfactory to counsel
for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise
to the same effect as the opinion required by Section&nbsp;5(b), 5(c) and 5(d) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Counsel for Underwriters</U>. If requested by the Representative, the favorable opinion of Latham &amp; Watkins LLP, counsel for the
Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to
the same effect as the opinion required by Section&nbsp;5(e) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down
Comfort Letter</U>. If requested by the Representative, a letter from Ernst &amp; Young GmbH Wirtschaftspr&uuml;fungsgesellschaft, in
form and substance satisfactory to the Representative and dated such Date of Delivery, substantially in the same form and substance as
the letter furnished to the Representative pursuant to Section 5(h) hereof, except that the &ldquo;specified date&rdquo; in the letter
furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Additional Documents</I>. At the Closing Time and at each Date of Delivery (if any) counsel for the Underwriters shall have
been furnished with such additional customary documents and opinions as they may reasonably require for the purpose of enabling them to
pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations
or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with
the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representative
and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and as required
to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is
after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option Securities, may be terminated by the
Representative by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such
termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections 1, 6,
7, 8, 13 and 14 shall survive any such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as
such term is defined in Rule 501(b) under the 1933 Act (each, an &ldquo;Affiliate&rdquo;)), its selling agents and each person, if any,
who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section 20 of the 1934 Act as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be
a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or
necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material
fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the
General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided
to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&ldquo;Marketing
Materials&rdquo;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically),
or the omission or alleged omission in any preliminary prospectus, Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication,
Prospectus or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <I>provided</I> that (subject to Section
6(c) below) any such settlement is effected with the written consent of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;against
any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel chosen by the Representative),
reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged
untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><I>provided</I>, <I>however,</I>
that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including
any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment
or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each
of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section
15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity
contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements
or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant
to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity
with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Actions
against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result
thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement.
In the case of parties indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected by the Representative.
An indemnifying party may participate at its own expense in the defense of any such action; <I>provided</I>, <I>however,</I> that counsel
to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no
event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate
from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the
same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written
consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification
or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential
parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all
liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission
of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Settlement
without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days
after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms
of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed
such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such
indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on
the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation
provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand,
in connection with the statements or omissions that resulted in such losses, liabilities, claims, damages or expenses, as well as any
other relevant equitable considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to
this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities
pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received
by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate public offering
price of the Securities as set forth on the cover of the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The relative fault of the
Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any
such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company and the Underwriters
agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses
incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably
incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding
by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement
or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Notwithstanding the provisions
of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting commissions received by such
Underwriter in connection with the Shares underwritten by it and distributed to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of this Section
7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and
each Underwriter&rsquo;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director
of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within
the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The
Underwriters&rsquo; respective obligations to contribute pursuant to this Section 7 are several in proportion to the number of Initial
Securities set forth opposite their respective names in Schedule A hereto and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations, Warranties and Agreements to Survive</U>. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and
in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents,
any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment
for the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Termination</I>. The Representative may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing
Time (i) if there has been, in the judgment of the Representative, since the time of execution of this Agreement or since the respective
dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse
change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries
considered as one enterprise, whether or not arising in the ordinary course of business, or (ii)&nbsp;if there has occurred any material
adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a prospective change in national or international political,
financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representative, impracticable
or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if
trading in any securities of the Company has been suspended or materially limited by the Commission or The Nasdaq Global Select Market,
or (iv) if trading generally on The Nasdaq Global Select Market has been suspended or materially limited, or minimum or maximum prices
for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission,
FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in commercial banking or securities settlement
or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium
has been declared by either Federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any
party to any other party except as provided in Section 4 hereof, and <I>provided further</I> that Sections 1, 6, 7, 8, 13 and 14 shall
survive such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time or a Date
of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &ldquo;Defaulted Securities&rdquo;),
the Representative shall have the right, within 24&nbsp;hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters,
or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and
upon the terms herein set forth; if, however, the Representative shall not have completed such arrangements within such 24-hour period,
then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(i) if the number
of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting Underwriters
shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting
obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">(ii) if the number
of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date
of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to sell, the Option Securities
to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any non-defaulting Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No action taken pursuant to
this Section shall relieve any defaulting Underwriter from liability in respect of its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In the event of any such default
which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after the Closing Time, which
does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities,
as the case may be, either the (i) Representative or (ii) the Company shall have the right to postpone Closing Time or the relevant Date
of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement,
the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term &ldquo;Underwriter&rdquo;
includes any person substituted for an Underwriter under this Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given
if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to Goldman Sachs at
200 West Street, New York, New York 10282, Attention: Registration Department, Jefferies at 520 Madison Avenue, New York, New York 10022,
Attention: General Counsel, and SVB Securities at 1301 Avenue of the Americas, 12<SUP>th</SUP> Floor, New York, New York 10019, Attention:
Stuart R. Nayman, Esq.; notices to the Company shall be directed to it at Friedrich-Miescher-Strasse 15, 72076, T&uuml;bingen, Germany,
attention of Mr. Franz-Werner Haas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a) the purchase and sale of the Securities
pursuant to this Agreement, including the determination of the public offering price of the Securities and any related discounts and commissions,
is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand,
and does not constitute a recommendation, investment advice, or solicitation of any action by the Underwriters, (b) in connection with
the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not
the agent or fiduciary of the Company, any of its subsidiaries or their respective shareholders, creditors, employees or any other party,
(c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering
of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company
or any of its subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the
Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged
in a broad range of transactions that involve interests that differ from those of the Company, (e) the Underwriters have not provided
any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate and (f) none of the activities of the Underwriters
in connection with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation of any action
by the Underwriters with respect to any entity or natural person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Recognition of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of this Section
13, a &ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance
with, 12 U.S.C. &sect; 1841(k). &ldquo;Covered Entity&rdquo; means any of the following: (i) a &ldquo;covered entity&rdquo; as that term
is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered bank&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). <B>&ldquo;</B>Default Right&rdquo; has the meaning assigned to that term in,
and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable. &ldquo;U.S. Special Resolution
Regime&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the
Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Parties</U>. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their
respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or
corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and
directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim
under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended
to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons
and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No
purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECTION 15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Trial
by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or proceeding arising out of or based upon this Agreement
or the transactions contemplated hereby (&ldquo;Related Proceedings&rdquo;) shall&nbsp;be instituted in (i) the federal courts of the
United States of America located in the City and County of New York, Borough of Manhattan or&nbsp;(ii) the courts of the State of New
York located in the City and County of New York, Borough of Manhattan (collectively, the &ldquo;Specified Courts&rdquo;), and each party
irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any
such court (a &ldquo;Related Judgment&rdquo;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action
or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s address set forth above shall be effective
service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive
any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally
waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been
brought in an inconvenient forum. Each party not located in the United States irrevocably appoints CureVac Inc. as its agent to receive
service of process or other legal summons for purposes of any such suit, action or proceeding that may be instituted in any state or federal
court in the City and County of New York. With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent
permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment
(both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any
Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not
raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including,
without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company agrees to indemnify
each Underwriter, each employee, officer and director of each Underwriter, and each person, if any, who controls any Underwriter within
the meaning of the Act and each broker-dealer or other affiliate of any Underwriter, against any loss incurred as a result of any judgment
or order being given or made for any amount due hereunder and such judgment or order being expressed and paid in a currency (the &ldquo;judgment
currency&rdquo;) other than U.S. dollars and as a result of any variation as between (i) the rate of exchange at which the U.S. dollar
amount is converted into the judgment currency for the purpose of such judgment or order, and (ii) the rate of exchange at which such
indemnified person is able to purchase U.S. dollars with the amount of the judgment currency actually received by the indemnified person.
The foregoing indemnity shall constitute a separate and independent obligation of the Company and shall continue in full force and effect
notwithstanding any such judgment or order as aforesaid. The term &ldquo;rate of exchange&rdquo; shall include any premiums and costs
of exchange payable in connection with the purchase of, or conversion into, the relevant currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER
TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts and Electronic Signatures</U>. This Agreement may be executed in any number of counterparts, each of which shall
be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Electronic signatures complying
with the New York Electronic Signatures and Records Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from time to time, or other
applicable law will be deemed original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission
method of an executed counterpart of this Agreement will constitute due and sufficient delivery of such counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">SECTION 21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Affiliates</U>. Sales of Common Shares made outside of the United States may be made by affiliates of the Underwriters acting
as their agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along
with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac N.V.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dr. Franz-Werner Haas</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIRMED AND ACCEPTED,</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date first above written:</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="padding-left: 27pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Goldman Sachs &amp; Co. LLC</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dan Cocks</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">jefferies LLC</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Charles Glazer</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">svb securities LLC</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gabriel Cavazos</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Senior Managing Director</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and as Representatives of the other Underwriters named
in Schedule A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The public offering price per share for the Securities shall be $9.25.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purchase price per share for the Securities to be paid by the several
Underwriters shall be $8.6950, being an amount equal to the public offering price set forth above less $0.5550 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Name of Underwriter</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Number of<BR> <U>Initial Securities</U></TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left; text-indent: -58.5pt; padding-left: 58.5pt">Goldman Sachs &amp; Co. LLC&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11,351,352</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -58.5pt; padding-left: 58.5pt">Jefferies LLC&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,108,108</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -58.5pt; padding-left: 58.5pt">SVB Securities LLC&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,756,757</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Van Lanschot Kempen (USA) Inc.&#9;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">810,811</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; padding-bottom: 2.5pt">Total&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">27,027,028</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch A-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Pricing Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is selling 27,027,028 Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 4,054,054 Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The public offering price
per share for the Securities shall be $9.25.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch B-1-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Free Writing Prospectuses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch B-2-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>List of Persons and Entities Subject to Lock-up</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">1.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Franz-Werner Haas</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">2.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Pierre Kemula</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">3.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Ralf Clemens</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">4.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Mathias Hothum</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">5.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Baron Jean St&eacute;phenne</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">6.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Hans Cristoph Tanner</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">7.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Craig A. Tooman</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">8.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Igor
Splawski</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">9.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Antony Blanc</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">10.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Viola Bronsema</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">11.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Myriam Mendila</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">12.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Malte Greune</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">13.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Klaus Schollmeier</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal; font-weight: normal; text-transform: uppercase">14.</FONT></TD><TD><FONT STYLE="font-variant: normal; font-weight: normal">Debra Barker</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">15.</TD><TD STYLE="text-align: justify">dievini Hopp BioTech holding GmbH &amp; Co. KG</TD>
</TR></TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch C-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><U>Written Testing-the-Water
Communications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> None.</P>



<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch D-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF OPINION OF COMPANY&rsquo;S AND CUREVAC&rsquo;S
COUNSEL<BR>
TO BE DELIVERED PURSUANT TO SECTION 5(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Assuming that the Underwriting Agreement has been duly authorized, executed and delivered by the Company insofar as Dutch law is concerned,
the Underwriting Agreement has been duly executed and delivered by the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Assuming that the Underwriting Agreement has been duly authorized, executed and delivered by the Company insofar as Dutch law is concerned,
under the laws of the State of New York relating to personal jurisdiction, the Company has, pursuant to Section 17 of the Underwriting
Agreement, validly and irrevocably submitted to the personal jurisdiction of any state or United States federal court located in the Borough
of Manhattan, the City of New York, New York (each a &ldquo;<B>New York Court</B>&rdquo;) in any action arising out of or relating to
the Underwriting Agreement or the transactions contemplated thereby, has validly and irrevocably waived to the fullest extent it may effectively
do so any objection to the venue of a proceeding in any such New York Court, and has validly and irrevocably appointed CureVac Inc. as
its authorized agent for the purpose described in Section 17 thereof; and service of process effected on such agent in the manner set
forth in Section 17 thereof will be effective to confer valid personal jurisdiction on the Company. We express no opinion as to whether
a New York State or United States federal court would enforce the exclusivity of the jurisdiction of any New York State or United States
federal court provided for in the Underwriting Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>The Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as
described in the Prospectus will not be, required to register as an &ldquo;<B>Investment Company</B>,&rdquo; as such term is defined in
the Investment Company Act of 1940, as amended.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>The execution and delivery by the Company of, and the performance by the Company of its obligations under, the Underwriting Agreement
will not contravene any provision of the statutory laws of the State of New York or any federal law of the United States of America that
in our experience is normally applicable to general business corporations in relation to transactions of the type contemplated thereby,
<I>provided</I> that we express no opinion as to federal or state securities laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>No consent, approval, authorization, or order of, or qualification with, any governmental body or agency under the laws of the State
of New York or any federal law of the United States of America that in our experience is normally applicable to general business corporations
in relation to transactions of the type contemplated by the Underwriting Agreement is required for the execution, delivery and performance
by the Company of its obligations under the Underwriting Agreement, except such as may be required under federal or state securities or
Blue Sky laws as to which we express no opinion.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit B-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF OPINION OF PARKERHIGHLANDER PLLC, THE COMPANY&rsquo;S
INTELLECTUAL PROPERTY COUNSEL TO BE DELIVERED PURSUANT TO SECTION 5(c)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">i.</TD><TD STYLE="text-align: left">Exhibit A attached hereto sets forth an accurate list of the Company United States Patents for which we
have acted as intellectual propert<FONT STYLE="color: #3F3F3F">y </FONT>counsel to the Company<FONT STYLE="color: #3F3F3F">;</FONT></TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">ii.</TD><TD STYLE="text-align: left">To our knowledge, the Company United States Patents have all been assigned by the named inventors to the
Company or its subsidiaries; except as disclosed in the Disclosure Documents and/or Exhibit A, the Company or its subsidiaries is listed
in the records of the United States Patent and Trademark Office (the &ldquo;<B><I>USPTO</I></B>&rdquo;) as the sole assignee of the Company
United States Patents; to our knowledge there are no currently asserted or unasserted claims of any persons disputing the inventorship
or ownership of any of the Company United States Patents; to our knowledge there are no liens, security interests or encumbrances that
have been filed against any of the Company United States Patents and such patents and applications are valid and in full effect;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">iii.</TD><TD STYLE="text-align: left">To our knowledge, there are no facts that are reasonably likely to provide a basis for a finding of unenforceability
or invalidity of any of granted patents listed in Exhibit A;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">iv.</TD><TD STYLE="text-align: left">To our knowledge, the pending applications within the Company United States Patents have been properly
filed on behalf of the Company or its subsidiaries and are being diligently prosecuted and duly maintained;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">v.</TD><TD STYLE="text-align: left">To our knowledge, the duty of candor and good faith as required by the USPTO during prosecution of the
patent applications listed in Exhibit A is being complied with; to our knowledge, all information material to the patentability of inventions
known to the inventors and the Company or its subsidiaries is being disclosed to the USPTO in accordance with 37 C.F.R. &sect; 1.56; to
our knowledge, all information submitted to the USPTO in connection with the prosecution of the Company United States Patents was and
is accurate in all material aspect;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">vi.</TD><TD STYLE="text-align: left">To our knowledge, no facts exist that have led us to the conclusion that the Company or its subsidiaries
lack or will be unable to obtain any rights to the Company United States Patents. We are not aware of any fact with respect to the patent
applications included in the Company United States Patents presently on file that (A) would necessarily preclude the issuance of patents
with respect to such applications, (B) would lead us to necessarily conclude that such patents, when issued, would not be valid and enforceable
in accordance with applicable regulations, or that any such patents issuing in respect of such applications would not be entitled to a
statutory presumption of validity and enforceability by the assignee, or (C) would result in a third party having any rights in any patents
issuing from such patent applications;</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-1-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">vii.</TD><TD STYLE="text-align: left">Except with respect to C.A. No. 1:22-cv-11202 filed in the United States District Court for the District
of Massachusetts, there are no pending or, to our knowledge, threatened claims, suits, judicial proceedings, interferences, oppositions,
or governmental proceedings (other than those associated with the normal examination and approval of pending patent applications) relating
to the Company United States Patents;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">viii.</TD><TD STYLE="text-align: left">To our knowledge, the product candidates mentioned in the Disclosure Documents as being developed by the
Company fall within the scope of the claims of one or more patent or patent application within the Company United States Patents owned
by the Company or its subsidiaries;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.5pt"></TD><TD STYLE="text-align: left; width: 40.5pt">ix.</TD><TD STYLE="text-align: left">To our knowledge, the operation of the Company or its subsidiaries, as now conducted or as proposed to
be conducted in the Disclosure Documents, does not conflict with, infringe, misappropriate or otherwise violate a valid claim of a patent
held by any third party; no actions, suits or proceedings have been asserted, threatened, or are pending against the Company or its subsidiaries
alleging infringement of a patent or other intellectual property right of any third party; and no court or government body, domestic or
foreign, has issued any order, judgment, decree, or injunction restricting the operation of the business of the Company or its subsidiaries
based on the intellectual property of a third party; except with respect to C.A. No. 1:22-cv-11202 filed in the United States District
Court for the District of Massachusetts, there are no pending actions, suits or proceedings related to infringements by others of any
of the Company United States Patents;</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 31.7pt"></TD><TD STYLE="text-align: left; width: 40.3pt">x.</TD><TD STYLE="text-align: left">To our knowledge, the statements and information relating to the Company&rsquo;s and or any of its subsidiaries&rsquo;
owned proprietary rights in the Intellectual Property Portions of each of the Disclosure Documents fairly and completely present the matters
disclosed therein and are accurate in all material respects; no facts have come to our attention that caused us to believe that: (i) the
Intellectual Property Portions to the extent they relate to Company United States Patents included in the Registration Statement, at the
time that the Registration Statement became effective, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein not misleading; (ii) to our knowledge, the Intellectual
Property Portions included in the General Disclosure Package, taken as a whole as of the Applicable Time, contained any untrue statement
of a material fact or omitted to state a material fact necessary, in order to make the statements therein, in light of the circumstances
under which they were made, not misleading; or (iii) to our knowledge, the Intellectual Property Portions included in the Prospectus,
as of its date or dates as amended or supplemented, as applicable, and as of the date hereof, contained or contains any untrue statement
of a material fact or omitted or omits to state a material fact necessary, in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-1-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit B-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF OPINION OF GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT
MBH, THE COMPANY&rsquo;S INTELLECTUAL PROPERTY COUNSEL TO BE DELIVERED PURSUANT TO SECTION 5(c)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">i. Exhibit A attached hereto sets forth a list of the Company European
and other non-US Patents provided by CureVac&rsquo;s IP department and not reviewed by ourselves in terms of completeness, for which we
have acted as intellectual property counsel to the Company. The undersigned is not responsible for the payment of maintenance fees since
January 1, 2021. Thus, the undersigned cannot make any statement as to the payment of maintenance fees since January 1, 2021 for the Company
European and other non-US Patents on Exhibit A and the status of these IP rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ii. To our knowledge, the Company European and other non-US Patents
have all been assigned by the named inventors to the Company or its subsidiaries except as disclosed in the Registration Statement; to
our knowledge, the Company or its subsidiaries is listed in the records as the assignee of the Company European and other non-US Patents
and, to our knowledge, there are no rights of third parties to the Company European or other non-US Patents except as disclosed in the
Registration Statement, and as disclosed by Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">iii. To our knowledge, there are no currently asserted or unasserted
claims of any persons disputing the inventorship or ownership of any of the Company European or other non-US Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">iv. To our knowledge, the pending applications within the Company European
and other non-US Patents have been properly filed on behalf of the Company or its subsidiaries and are being diligently prosecuted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">v. To our knowledge, there are no pending or threatened claims, suits,
judicial proceedings, interferences or governmental proceedings (other than those associated with the normal examination and approval
of pending patent applications) relating to the Company European</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and other non-US States Patents, other than various opposition proceedings
in Europe and Australia, and other than listed in Exhibit B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">vi. We are not aware of any fact with respect to the patent applications
included in the Company European and other non-US Patents presently on file that would result in a third party having any rights in any
patents issuing from such patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">vii. To our knowledge, all of the product candidates mentioned in the
Disclosure Documents as being developed by the Company fall within the scope of the claims of one or more patent or patent application
within the Company European and other non-US Patents owned (or co-owned) by the Company or its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">viii. To our knowledge, no actions, suits or proceedings have been
asserted, threatened, or are pending against the Company or its subsidiaries alleging infringement of a patent or other intellectual property
right of any third party in Europe or other non-US countries; and no court or government body, domestic or foreign, has issued any order,
judgment, decree, or injunction restricting the operation of the business of the Company or its subsidiaries based on the intellectual
property of a third party in Europe or other non-US countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ix. The Company currently asserts European/German IP rights against
another party before the D&uuml;sseldorf Court, claiming damages resulting from third party&rsquo;s marketing of a Covid 19 mRNA vaccine.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-2-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF OPINION OF NAUTADUTILH N.V., THE COMPANY&rsquo;S
DUTCH COUNSEL TO BE DELIVERED PURSUANT TO SECTION 5(d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Incorporation and Corporate Status</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: left">The Company has been duly incorporated as a <I>besloten vennootschap met beperkte aansprakelijkheid</I>
and is validly existing as a <I>naamloze vennootschap</I>.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Corporate Power</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: left">The Company has the corporate power (i) to enter into the Offering Documents and to perform its obligations
thereunder, (ii) to issue the Offer Shares [and the Option Shares] pursuant to the Deed of Issue of Offer Shares [and the Deed of Issue
of Option Shares, respectively,] and (iii) to exclude pre-emption rights (<I>voorkeursrechten</I>) with respect to such issuance of Offer
Shares and the granting of the Option, as a consequence of which no pre-emption rights (<I>voorkeursrechten</I>) apply with respect to
such issuance of Option Shares. The Company does not violate any provision of its Articles of Association by (i) entering into the Offering
Documents and performing its obligations thereunder, (ii) issuing the Offer Shares [and the Option Shares] pursuant to the Deed of Issue
of Offer Shares [and the Deed of Issue of Option Shares, respectively,] and (iii) excluding pre-emption rights (<I>voorkeursrechten</I>)
with respect to such issuance of Offer Shares and the granting of the Option, as a consequence of which no pre-emption rights (<I>voorkeursrechten</I>)
apply with respect to such issuance of Option Shares.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Corporate Action</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: left">The Company has taken all corporate action required by its Articles of Association and Dutch law in connection
with the Company (i) entering into the Offering Documents and performing its obligations thereunder, (ii) issuing the Offer Shares [and
the Option Shares] pursuant to the Deed of Issue of Offer Shares [and the Deed of Issue of Option Shares, respectively,] and (iii) excluding
pre-emption rights (<I>voorkeursrechten</I>) with respect to such issuance of Offer Shares and the granting of the Option, as a consequence
of which no pre-emption rights (<I>voorkeursrechten</I>) apply with respect to such issuance of Option Shares.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Valid Signing</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: left">The Offering Documents have been validly signed on behalf of the Company.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Offer Shares </B>[<B>and Option Shares</B>]</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="text-align: left">The Offer Shares [and the Option Shares] have been validly issued pursuant to the Deed of Issue of Offer
Shares [and the Deed of Issue of Option Shares, respectively,] and, subject to receipt by the Company of payment in full for the Offer
Shares [and the Option Shares] as provided for in the Offering Documents, are fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit C-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Pre-emption Rights </B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD><TD STYLE="text-align: left">The pre-emption rights (<I>voorkeursrechten</I>) with respect to the issuance of the Offer Shares have
been validly excluded. The pre-emption rights (<I>voorkeursrechten</I>) with respect to the granting of the Option have been validly excluded,
as a consequence of which no pre-emption rights (<I>voorkeursrechten</I>) apply with respect to the issuance of the Option Shares.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left"><B>Statements in the Registration
Statement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.</FONT></TD><TD STYLE="text-align: left">All statements made in the Registration Statement under the captions &quot;<I>Description of Share Capital
and Articles of Association</I>&quot;, in respect of Dutch law or the Current Articles and to the extent they do not relate to factual
statements, are true and accurate in all material respects and provide fair summaries of the matters of Dutch law or the Current Articles,
as the case may be, as referred to therein as at the date of the Registration Statement.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.</FONT></TD><TD STYLE="text-align: left">All statements made in the Registration Statement under the caption &quot;<I>Taxation</I>&mdash;<I>Material
Dutch Tax Considerations</I>&quot;, in each case in respect of Dutch tax law and to the extent they do not relate to factual statements,
provide a fair summary of the matters of Dutch tax law as referred to therein and that summary is true and accurate in all material respects
as at the date of the Registration Statement, subject to the introduction and exceptions in the first paragraphs of such statement.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Authorised Share Capital</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt">9.</TD><TD STYLE="text-align: left">The authorized share capital (<I>maatschappelijk kapitaal</I>) of the Company amounts to EUR 92,700,000
divided into 386,250,000 ordinary shares and 386,250,000 preferred shares with a nominal value of EUR 0.12 each.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Choice of Law / Enforceability</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.</FONT></TD><TD STYLE="text-align: left">The choice of the laws of the State of New York to govern the obligations of the Company under the Underwriting
Agreement is recognised under Dutch law and, accordingly, the enforceability of those obligations is determined under Dutch law by reference
to the laws of the State of New York.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.</FONT></TD><TD STYLE="text-align: left">The choice of Dutch law to govern the obligations of the Company under the Deed of Issue of Offer Shares
[and the Deed of Issue of Option Shares] is a legal, valid and binding choice of law, which is recognised under Dutch law and will be
given effect to by the Dutch courts.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.</FONT></TD><TD STYLE="text-align: left">The obligations of the Company under the Deed of Issue of Offer Shares [and the Deed of Issue of Option
Shares] constitute the legal, valid and binding obligations of the Company, enforceable against it in the Netherlands in accordance with
their terms.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Choice of Law Appointment Process Agent</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.</FONT></TD><TD STYLE="text-align: left">The choice of the laws of the State of New York to govern the appointment by the Company of an agent for
service of process in the Underwriting Agreement is recognised under Dutch law.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit C-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>No Violation of Law</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.</FONT></TD><TD STYLE="text-align: left">The (i) entering into of the Offering Documents and the performance of its obligations thereunder, (ii)
the issuance of the Offer Shares [and the Option Shares] pursuant to the Deed of Issue of Offer Shares [and the Deed of Issue of Option
Shares, respectively,] and (iii) the exclusion of pre-emption rights (<I>voorkeursrechten</I>) with respect to such issuance of Offer
Shares and the granting of the Option, as a consequence of which no pre-emption rights (<I>voorkeursrechten</I>) apply with respect to
such issuance of Option Shares, in each case by the Company, does not in itself result in a violation of Dutch law.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>No Authorisations, Consents or Approvals</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.</FONT></TD><TD STYLE="text-align: left">No authorisation, consent, approval, licence or order from or notice to or filing with any regulatory
or other authority or governmental body of the Netherlands is required by the Company in order to allow under Dutch law (i) its entering
into of the Offering Documents and the performance of its obligations thereunder, (ii) the issuance of the Offer Shares [and the Option
Shares] pursuant to the Deed of Issue of Offer Shares [and the Deed of Issue of Option Shares, respectively,] and (iii) the exclusion
of pre-emption rights (<I>voorkeursrechten</I>) with respect to such issuance of Offer Shares and the granting of the Option, as a consequence
of which no pre-emption rights (<I>voorkeursrechten</I>) apply with respect to such issuance of Option Shares.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Jurisdiction</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.</FONT></TD><TD STYLE="text-align: left">The agreement conferring jurisdiction in the Underwriting Agreement is recognised under Dutch law and
will be given effect to by the Dutch courts.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>No Immunity</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.</FONT></TD><TD STYLE="text-align: left">The Company does not enjoy any right of immunity from legal proceedings in the Netherlands in relation
to the Offering Documents, it cannot claim immunity from the enforcement of judgments of Dutch courts and its assets located in the Netherlands
do not enjoy immunity from attachment or enforcement in the Netherlands.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>Enforcement of Judgments</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.</FONT></TD><TD STYLE="text-align: left">A judgment of the federal courts of the United States of America located in the Borough of Manhattan in
the City of New York or the state courts of the State of New York in each case located in the Borough of Manhattan in the City of New
York (collectively, the &quot;<B>Specified Courts</B>&quot;) cannot be enforced in the Netherlands. In order to obtain a judgment in respect
of the Underwriting Agreement that can be enforced in the Netherlands against the Company, the dispute will have to be re-litigated before
the competent Dutch court. This court will have discretion to attach such weight to the judgment of the Specified Courts as it deems appropriate.
Given the submission by the Company to the jurisdiction of any Specified Courts, the Dutch courts can be expected to give conclusive effect
to a final and enforceable judgment of such court in respect of the obligations under the Underwriting Agreement without re-examination
or re-litigation of the substantive matters adjudicated upon. This would require (i) the court involved accepted jurisdiction on the basis
of an internationally recognised ground to accept jurisdiction, (ii) the proceedings before such court to have complied with principles
of proper procedure (<I>behoorlijke rechtspleging</I>), (iii) such judgment not being contrary to the public policy of the Netherlands
and (iv) such judgment not being incompatible with a judgment given between the same parties by a Dutch court or with a prior judgment
given between the same parties by a foreign court in a dispute concerning the same subject matter and based on the same cause of action,
provided such prior judgment is recognisable in the Netherlands.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit C-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left"><B>No Tax Residency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.</FONT></TD><TD STYLE="text-align: left">None of the Addressees will become or deemed to become resident or domiciled in the Netherlands for Dutch
tax purposes or otherwise become subject to Dutch taxation on income or capital gains by reason only of the signing or enforcement of
the Underwriting Agreement or the performance by the Company of its obligations under the Underwriting Agreement.</TD></TR></TABLE>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left"><B>No Stamp Duties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.</FONT></TD><TD STYLE="text-align: left">No Dutch documentation taxes (commonly referred to as stamp duties) will be payable by the Addressees
in respect of or in connection with the signing of the Underwriting Agreement or the performance by the Company of its obligations under
the Underwriting Agreement.</TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit C-4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form of
lock-up from directors, officers or other stockholders<BR>
pursuant to Section 5(</FONT>l<FONT STYLE="text-transform: uppercase">)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned, an officer
and/or director of CureVac N.V., a Dutch public company with limited liability (<I>naamloze vennootschap</I>) (the &ldquo;Company&rdquo;),
understands that Goldman Sachs &amp; Co. LLC (&ldquo;Goldman Sachs&rdquo;), Jefferies LLC (&ldquo;Jefferies&rdquo;) and SVB Securities
LLC (&ldquo;SVB Securities,&rdquo; together with Goldman Sachs and Jefferies, the &ldquo;Representatives&rdquo;) propose to enter into
an Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with the Company providing for the public offering (the &ldquo;Offering&rdquo;)
of the Company&rsquo;s common shares, par value &euro;0.12 per share (the &ldquo;Common Shares&rdquo;). In recognition of the benefit
that such an offering will confer upon the undersigned as a stockholder and/or a supervisory board member or management board member of
the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned
agrees with each Underwriter that, during the period beginning on the date hereof and ending on the date that is 60 days from the date
of the Underwriting Agreement (the &ldquo;Lock-up Period&rdquo;), the undersigned will not, without the prior written consent of the Representatives,
(i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any Common Shares or any securities convertible
into or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the undersigned or with respect to which
the undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;Lock-Up Securities&rdquo;), or exercise any
right with respect to the registration of any of the Lock-Up Securities, or file, cause to be filed or cause to be confidentially submitted
any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii) enter into any swap or any other
agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the
Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Shares or other securities, in cash or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the undersigned is a supervisory
board member or management board member of the Company, the Representative agrees that, at least three business days before the effective
date of any release or waiver of the foregoing restrictions in connection with a transfer of Common Shares, the Representative will notify
the Company of the impending release or waiver. The provisions of this paragraph will not apply if (i) the release or waiver is effected
solely to permit a transfer not for consideration and (ii) the transferee has agreed in writing to be bound by the same terms described
in this letter agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The restrictions set forth
in the preceding paragraphs shall not apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift or gifts, pursuant to a will or other
testamentary document, (b) to any trust for the direct or indirect benefit of the undersigned, (c) to the immediate family of the undersigned,
(d) to an affiliate (as defined below) of the undersigned or (e) to any investment vehicle or affiliates thereof controlled by the immediate
family of the undersigned (for purposes of this letter agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood,
marriage or adoption, not more remote than first cousin);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers (whether for consideration
or for no value): (a) to any stockholder, partner or member of, or owner of a similar equity interest in, the undersigned, (b) to the
ultimate beneficiary of the undersigned or his/her respective immediate family, (c) to any family foundation or trust established by the
before mentioned under (b) (not for value), or (d) to any affiliate of the before mentioned under (a) through (c), as the case may be;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exhibit D-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned
(a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&rsquo;s
capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially
all of the undersigned&rsquo;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this letter
agreement or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee is
an affiliate of the undersigned, or to any investment fund controlled or managed by the undersigned or any of its affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
transfers made pursuant to a court or regulatory agency order, such as pursuant to a qualified domestic order or in connection with a
divorce settlement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;transfers
of Common Shares or any security convertible into Common Shares made by the undersigned to the Company or existing stockholders in the
Company solely to satisfy tax withholding obligations or in connection with a cashless exercise pursuant to the Company&rsquo;s equity
incentive plans or arrangements disclosed in the final prospectus relating to the Offering, including, for the avoidance of doubt, VSOPs
or Prior VSOPs, as defined in the Registration Statement of the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
transfer of Common Shares, or other securities convertible into or exercisable or exchangeable for Common Shares, in each case acquired
in open market transactions after completion of the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;the
entry, by the undersigned, at any time on or after the date of the Underwriting Agreement, of any trading plan providing for the sale
of Common Shares by the undersigned, which trading plan meets the requirements of Rule 10b5-1 under the Exchange Act (a &ldquo;Rule 10b5-1
Plan&rdquo;), <I>provided</I>, <I>however</I>, that (a) such plan does not provide for, or permit, the sale of any Common Shares during
the Lock-Up Period and (b) no public announcement or filing is voluntarily made or required, including in any filings under the Exchange
Act, regarding such plan during the Lock-Up Period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(viii)&nbsp;&nbsp;&nbsp;transactions
pursuant to a Rule 10b5-1 Plan, entered into by the undersigned prior to the date hereof; provided that any filings made under the Exchange
Act upon any sales during the Lock-Up Period shall clearly indicate that such sales were pursuant to a Rule 10b5-1 Plan; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
transfer of Common Shares or any security convertible into or exercisable or exchangeable for Common Shares pursuant to a bona fide third-party
tender offer, merger, consolidation or other similar transaction made to all holders of the Company&rsquo;s securities involving a change
of control of the ownership of the Company, <I>provided</I> that in the event that such tender offer, merger, consolidation or other such
transaction is not completed, such securities held by the undersigned shall remain subject to the restrictions on transfer set forth in
this letter agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>provided</I>, <I>however</I>,
that in the case of any transfer described in clause (i) through (v) above, it shall be a condition to the transfer that the transferee
executes and delivers to the Representative a written agreement, in substantially the form of this letter agreement (it being understood
that any references to &ldquo;immediate family&rdquo; in the agreement executed by such transferee shall expressly refer only to the immediate
family of the undersigned and not to the immediate family of the transferee) and otherwise reasonably satisfactory in form and substance
to the Representative; <I>provided further</I>, for the avoidance of doubt, that in the case of any transfer permitted in this letter
agreement, any filing required under Section 16 of the Exchange Act to be made during the Lock-Up Period shall include a statement to
the effect that (A) such transaction reflects the circumstances described herein and (B) the Common Shares received or transferred are
subject to this letter agreement (as applicable). For the purposes of clause (viii), &ldquo;change of control&rdquo; shall mean the transfer
(whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions,
to a person or group of affiliated persons (other than an Underwriter pursuant to the Offering), of the Company&rsquo;s voting securities
if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the
Company (or the surviving entity). The term &ldquo;affiliate&rdquo; in this letter agreement shall have the meaning set forth in Rule
405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exhibit D-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For avoidance of doubt, nothing
in this letter agreement prohibits the undersigned from receiving, exercising or exchanging any options or warrants to acquire Common
Shares or any securities convertible into, exchangeable for or that represent the right to receive Common Shares of the Company (which
exercises may be effected on a cash or cashless basis to the extent the instruments representing such options or warrants permit exercises
on a cash or cashless basis), including under the Company&rsquo;s existing equity plans or pursuant to new or amended equity plans, it
being understood that any Common Shares issued upon such exercises or exchanges, or pursuant to such existing or new plans or amendments,
(i) will be subject to the restrictions of this letter agreement, and (ii) if required, any public report or filing under Section 16 of
the Exchange Act shall clearly indicate in the footnotes thereto that (A) the filing relates to the exercise of a share option, (B) that
no Common Shares were sold by the reporting person and (C) that Common Shares received upon exercise of the share option are subject to
this letter agreement with the underwriters of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer of
the Lock-Up Securities except in compliance with the foregoing restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If (i) the Company notifies
the Representative in writing that it does not intend to proceed with the Offering, (ii) the Underwriting Agreement is not executed by
February 28, 2023 (<I>provided</I> that the Company may, by written notice to the undersigned prior to such date, extend such date for
an additional 30 days), or (iii) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated for any reason prior to payment for and delivery of any Common Shares to be sold thereunder, then this letter agreement
shall immediately be terminated and the undersigned shall automatically be released from all of his or her obligations under this letter
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Print Name:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 427pt; text-indent: -211pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit D-7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm236242d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">ATTORNEYS &bull; CIVIL LAW NOTARIES &bull; TAX ADVISERS</TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">P.O. Box 7113&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1007 JC Amsterdam&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">Beethovenstraat 400</TD>
  <TD STYLE="padding-left: 0.375in; width: 50%">Amsterdam, 10 February 2023.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1082 PR Amsterdam&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T +31 20 71 71 000&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">F +31 20 71 71 111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We have acted as legal
counsel as to Dutch law to the Company in connection with the Offering and the filing of the Registration Statement with the SEC. This
opinion letter is rendered to you in order to be filed with the SEC as an exhibit to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Capitalised terms used
in this opinion letter have the meanings set forth in Exhibit A to this opinion letter. The section headings used in this opinion letter
are for convenience of reference only and are not to affect its construction or to be taken into consideration in its interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This opinion letter is
strictly limited to the matters stated in it and may not be read as extending by implication to any matters not specifically referred
to in it. Nothing in this opinion letter should be taken as expressing an opinion in respect of any representations or warranties, or
other information, contained in any document reviewed by us in connection with this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In rendering the opinions
expressed in this opinion letter, we have reviewed and relied upon drafts of the Reviewed Documents, a draft of the Registration Statement
and pdf copies or drafts, as the case may be, of the Corporate Documents and we have assumed that the Reviewed Documents shall be entered
into for bona fide commercial reasons. We have not investigated or verified any factual matter disclosed to us in the course of our review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This opinion letter sets
out our opinion on certain matters of the laws with general applicability of the Netherlands, and, insofar as they are directly applicable
in the Netherlands, of the European Union, as at today's date and as presently interpreted under published authoritative case law of
the Dutch courts, the General Court and the Court of Justice of the European Union. We do not express any opinion on Dutch or European
competition law, data protection law, tax law, securitisation law or regulatory law. No undertaking is assumed on our part to revise,
update or amend this opinion letter in connection with, or to notify or inform you of, any developments and/or changes of Dutch law subsequent
to today's date. We do not purport to opine on the consequences of amendments to the Reviewed Documents, the Registration Statement or
the Corporate Documents subsequent to the date of this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The opinions expressed
in this opinion letter are to be construed and interpreted in accordance with Dutch law. The competent courts at Amsterdam, the Netherlands,
have exclusive jurisdiction to settle any issues of interpretation or liability arising out of or in connection with this opinion letter.
Any legal relationship arising out of or in connection with this opinion letter (whether contractual or non-contractual), including the
above submission to jurisdiction, is governed by Dutch law and shall be subject to the general terms and conditions of NautaDutilh. Any
liability arising out of or in connection with this opinion letter shall be limited to the amount which is paid out under NautaDutilh's
insurance policy in the matter concerned. No person other than NautaDutilh may be held liable in connection with this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">All legal relationships
are subject to NautaDutilh N.V.'s general terms and conditions (see https://www.nautadutilh.com/terms), which apply mutatis mutandis
to our relationship with third parties relying on statements of NautaDutilh N.V., include a limitation of liability clause, have been
filed with the Rotterdam District Court and will be provided free of charge upon request. NautaDutilh N.V.; corporate seat Rotterdam;
trade register no. 24338323.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 123pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this opinion letter, legal concepts are expressed
in English terms. The Dutch legal concepts concerned may not be identical in meaning to the concepts described by the English terms as
they exist under the law of other jurisdictions. In the event of a conflict or inconsistency, the relevant expression shall be deemed
to refer only to the Dutch legal concepts described by the English terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the purposes of this opinion letter, we have assumed that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">a.</TD><TD STYLE="text-align: justify">drafts of documents
                                            reviewed by us will be signed in the form of those drafts, each copy of a document conforms
                                            to the original, each original is authentic, and each signature is the genuine signature
                                            of the individual purported to have placed that signature;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">b.</TD><TD STYLE="text-align: justify">if any signature under
                                            any document is an electronic signature (as opposed to a handwritten (&quot;wet ink&quot;)
                                            signature) only, it is either a qualified electronic signature within the meaning of the
                                            eIDAS Regulation, or the method used for signing is otherwise sufficiently reliable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">c.</TD><TD STYLE="text-align: justify">the Registration Statement
                                            has been or will be declared effective by the SEC in the form reviewed by us;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">d.</TD><TD STYLE="text-align: justify">at each Relevant Moment,
                                            Ordinary Shares shall have been admitted for trading on a regulated market, a multilateral
                                            trading facility or a comparable trading system outside the European Economic Area as referred
                                            to in Section 2:86c(1) DCC;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">e.</TD><TD STYLE="text-align: justify">(i) no internal regulations
                                            (<I>reglementen</I>) have been adopted by any corporate body of the Company which would affect
                                            the validity of the resolutions recorded in the Resolutions and (ii) the Current Articles
                                            are the Articles of Association currently in force and as they will be in force at each Relevant
                                            Moment;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 123pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">f.</TD><TD STYLE="text-align: justify">(i) at each Relevant
                                            Moment, the resolutions recorded in the Resolutions shall be in full force and effect, (ii)
                                            at each Relevant Moment, the factual statements made and the confirmations given in the Resolutions
                                            and in each Deed of Issue shall be complete and correct and (iii) the Resolutions correctly
                                            reflect the resolutions recorded therein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">g.</TD><TD STYLE="text-align: justify">at each Relevant Moment,
                                            the authorised share capital (<I>maatschappelijk kapitaal</I>) of the Company shall allow
                                            for the issuance of the Offer Shares and the Option Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">h.</TD><TD STYLE="text-align: justify">at a Relevant Moment,
                                            the relevant Deed of Issue shall have been validly signed and executed on behalf of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">i.</TD><TD STYLE="text-align: justify">the Offering, to the
                                            extent made in the Netherlands, has been, is and will be made in conformity with the Prospectus
                                            Regulation and the rules promulgated thereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">j.</TD><TD STYLE="text-align: justify">the Option (i) has
                                            been validly granted as a right to subscribe for Ordinary Shares (<I>recht tot het nemen
                                            van aandelen</I>), (ii) shall be in full force and effect upon being exercised and (iii)
                                            shall have been validly exercised in accordance with the terms of the Underwriting Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon and subject to the foregoing and subject
to the qualifications set forth in this opinion letter and to any matters, documents or events not disclosed to us, we express the following
opinions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Corporate Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt; text-align: left">1.</TD><TD STYLE="text-align: justify">The Company has been
                                            duly incorporated as a <I>besloten vennootschap met beperkte aansprakelijkheid </I>and is
                                            validly existing as a <I>naamloze vennootschap</I>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Offer Shares and Option Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt">2.</TD><TD STYLE="text-align: justify">Subject to receipt by the Company of
                                            payment in full for the Offer Shares and the Option Shares as provided for in the Reviewed
                                            Documents, and when issued and accepted in accordance with the Resolutions and the Reviewed
                                            Documents, the Offer Shares and the Option Shares shall be validly issued, fully paid and
                                            non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opinions expressed above are subject to the following qualifications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45pt"></TD><TD STYLE="width: 35.55pt">A.</TD><TD STYLE="text-align: justify">Opinion 1 must not be read to imply
                                            that the Company cannot be dissolved (<I>ontbonden</I>). A company such as the Company may
                                            be dissolved, inter alia by the competent court at the request of the company's board of
                                            directors, any interested party (<I>belanghebbende</I>) or the public prosecution office
                                            in certain circumstances, such as when there are certain defects in the incorporation of
                                            the company. Any such dissolution will not have retro-active effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.55pt">B.</TD><TD STYLE="text-align: justify">Pursuant to Section 2:7 DCC, any transaction
                                            entered into by a legal entity may be nullified by the legal entity itself or its liquidator
                                            in bankruptcy proceedings (<I>curator</I>) if the objects of that entity were transgressed
                                            by the transaction and the other party to the transaction knew or should have known this
                                            without independent investigation (<I>wist of zonder eigen onderzoek moest weten</I>). The
                                            Dutch Supreme Court (<I>Hoge Raad der Nederlanden</I>) has ruled that in determining whether
                                            the objects of a legal entity are transgressed, not only the description of the objects in
                                            that legal entity's articles of association (<I>statuten</I>) is decisive, but all (relevant)
                                            circumstances must be taken into account, in particular whether the interests of the legal
                                            entity were served by the transaction. Based on the objects clause contained in the Current
                                            Articles, we have no reason to believe that, by entering into the Reviewed Documents, the
                                            Company would transgress the description of the objects contained in its Articles of Association.
                                            However, we cannot assess whether there are other relevant circumstances that must be taken
                                            into account, in particular whether the interests of the Company are served by entering into
                                            the Reviewed Documents since this is a matter of fact.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.55pt">C.</TD><TD STYLE="text-align: justify">Pursuant to Section 2:98c DCC, a company
                                            such as the Company may grant loans (<I>leningen verstrekken</I>) only in accordance with
                                            the restrictions set out in Section 2:98c DCC, and may not provide security (<I>zekerheid
                                            stellen</I>), give a price guarantee (<I>koersgarantie geven</I>) or otherwise bind itself,
                                            whether jointly and severally or otherwise with or for third parties (<I>zich op andere wijze
                                            sterk maken of zich hoofdelijk of anderszins naast of voor anderen verbinden</I>) with a
                                            view to (<I>met het oog op</I>) the subscription or acquisition by third parties of shares
                                            in its share capital or depository receipts. This prohibition also applies to its subsidiaries
                                            (<I>dochtervennootschappen</I>). It is generally assumed that a transaction entered into
                                            in violation of Section 2:98c DCC is null and void (<I>nietig</I>). Based on the content
                                            of the Reviewed Documents, we have no reason to believe that the Company or its subsidiaries
                                            will violate Section 2:98c DCC in connection with the issue of the Offer Shares or the Option
                                            Shares. However, we cannot confirm this definitively, since the determination of whether
                                            a company (or a subsidiary) has provided security, has given a price guarantee or has otherwise
                                            bound itself, with a view to the subscription or acquisition by third parties of shares in
                                            its share capital or depository receipts, as described above, is a matter of fact.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.55pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.55pt">D.</TD><TD STYLE="text-align: justify">The opinions expressed in this opinion letter
                                            may be limited or affected by:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify">rules
                                            relating to Insolvency Proceedings or similar proceedings under a foreign law and other rules
                                            affecting creditors' rights generally;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt">b.</TD><TD STYLE="text-align: justify">the provisions of fraudulent preference
                                            and fraudulent conveyance (<I>Actio Pauliana</I>) and similar rights available in other jurisdictions
                                            to insolvency practitioners and insolvency office holders in bankruptcy proceedings or creditors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify">claims
                                            based on tort (<I>onrechtmatige daad</I>);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify">sanctions
                                            and measures, including but not limited to those concerning export control, pursuant to European
                                            Union regulations, under the Dutch Sanctions Act 1977 (<I>Sanctiewet 1977</I>) or other legislation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt"><FONT STYLE="font-size: 10pt">e.</FONT></TD><TD STYLE="text-align: justify">the
                                            Anti-Boycott Regulation, Anti Money Laundering Laws and related legislation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt">f.</TD><TD STYLE="text-align: justify">any intervention, recovery or resolution
                                            measure by any regulatory or other authority or governmental body in relation to financial
                                            enterprises or their affiliated entities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.4pt"></TD><TD STYLE="width: 35.15pt">g.</TD><TD STYLE="text-align: justify">the rules of force majeure (<I>niet
                                            toerekenbare tekortkoming</I>), reasonableness and fairness (<I>redelijkheid en billijkheid</I>),
                                            suspension (<I>opschorting</I>), dissolution (<I>ontbinding</I>), unforeseen circumstances
                                            (<I>onvoorziene omstandigheden</I>) and vitiated consent (i.e., duress (<I>bedreiging</I>),
                                            fraud (<I>bedrog</I>), abuse of circumstances (<I>misbruik van omstandigheden</I>) and error
                                            (<I>dwaling</I>)) or a difference of intention (<I>wil</I>) and declaration (<I>verklaring</I>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.55pt">E.</TD><TD STYLE="text-align: justify">The term &quot;non-assessable&quot; has no
                                            equivalent in the Dutch language and for purposes of this opinion letter such term should
                                            be interpreted to mean that a holder of an Ordinary Share shall not by reason of merely being
                                            such a holder be subject to assessment or calls by the Company or its creditors for further
                                            payment on such Ordinary Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.55pt">F.</TD><TD STYLE="text-align: justify">This opinion letter does not purport to express
                                            any opinion or view on the operational rules and procedures of any clearing or settlement
                                            system or agency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the filing of this opinion letter
as an exhibit to the Registration Statement and also consent to the reference to NautaDutilh in the Registration Statement under the
caption &quot;Legal Matters&quot;. In giving this consent we do not admit or imply that we are a person whose consent is required under
Section 7 of the United States Securities Act of 1933, as amended, or any rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ NautaDutilh N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 30%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
    A</B></FONT></TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIST
    OF DEFINITIONS</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Anti
    Money Laundering Laws</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The European Anti-Money Laundering Directives, as implemented
    in the Netherlands in the Money Laundering and Terrorist Financing Prevention&nbsp;&nbsp;Act&nbsp;&nbsp;(<I>Wet&nbsp;&nbsp;ter&nbsp;&nbsp;voorkoming&nbsp;&nbsp;van
    witwassen en financieren van terrorisme</I>) and the Dutch Criminal Code (<I>Wetboek van Strafrecht</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Anti-Boycott
    Regulation</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Council Regulation (EC) No 2271/96 of 22 November
    1996 on protecting against the effects of the extra-territorial application of legislation adopted by a third country, and actions
    based thereon or resulting therefrom.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Articles
    of Association</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company's articles of association (<I>statuten</I>)
    as they read from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Bankruptcy
    Code</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Dutch Bankrupcty Code (<I>Faillissementswet</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Commercial
    Register</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Dutch Commercial Register (<I>handelsregister</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Company</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac N.V., a public company with limited liability&nbsp;&nbsp;(<I>naamloze&nbsp;&nbsp;vennootschap</I>),&nbsp;&nbsp;registered
    with&nbsp;&nbsp;the&nbsp;&nbsp;Commercial&nbsp;&nbsp;Register&nbsp;&nbsp;under&nbsp;&nbsp;number 77798031.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Corporate
    Documents</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&nbsp;&nbsp;Deed&nbsp;&nbsp;of&nbsp;&nbsp;Incorporation,&nbsp;&nbsp;the&nbsp;&nbsp;Deed&nbsp;&nbsp;of
    Conversion,&nbsp;&nbsp;the&nbsp;&nbsp;&nbsp;Current&nbsp;&nbsp;Articles&nbsp;&nbsp;and&nbsp;&nbsp;the Resolutions.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Current
    Articles</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Articles of Association as contained in the Deed
    of Conversion.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>DCC</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Dutch Civil Code (<I>Burgerlijk Wetboek</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Deed
    of Conversion</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The deed of conversion and amendment to the Articles
    of Association dated 14 August 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Deed
    of Incorporation</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company's deed of incorporation (<I>akte van oprichting)
    dated 7 April 2020.</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 30%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Deed
    of Issue</B>&quot;</FONT></TD>
    <TD STYLE="width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The draft deed of issue of the Offer
    Shares or Option Shares, as the case may be, prepared by us with references 82044152 M 51840756 and 82044152 M 51840709, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>eIDAS
    Regulation</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation (EU) No 910/2014 of the European Parliament
    and of the Council of 23 July 2014 on electronic&nbsp;&nbsp;identification&nbsp;&nbsp;and&nbsp;&nbsp;trust&nbsp;&nbsp;services&nbsp;&nbsp;for
    electronic transactions in the internal market and repealing Directive 1999/93/EC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>General
    Meeting</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&nbsp;&nbsp;Company's&nbsp;&nbsp;general&nbsp;&nbsp;meeting&nbsp;&nbsp;(<I>algemene
    vergadering</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Insolvency
    Proceedings</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any insolvency proceedings within the meaning of Regulation
    (EU) 2015/848 of the European Parliament and of the Council of 20 May 2015 on insolvency proceedings (recast), as amended by Regulation&nbsp;&nbsp;(EU)
    &nbsp;2021/2260&nbsp;of&nbsp;the&nbsp;&nbsp;European Parliament and of the Counsel of 15 December 2021, listed in Annex A thereto
    and any statutory proceedings&nbsp;&nbsp;for&nbsp;&nbsp;the&nbsp;&nbsp;restructuring&nbsp;&nbsp;of debts (<I>akkoordprocedure</I>)
    pursuant to the Bankruptcy Code.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Management
    Board</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company's management board (<I>bestuur</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>NautaDutilh</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NautaDutilh N.V.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>the
    Netherlands</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The European territory of the Kingdom of the Netherlands&nbsp;&nbsp;and&nbsp;&nbsp;&quot;<B>Dutch</B>&quot;&nbsp;&nbsp;is&nbsp;&nbsp;in&nbsp;&nbsp;or&nbsp;&nbsp;from&nbsp;&nbsp;the
    Netherlands.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Offer
    Shares</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,027,028 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Offering</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The offering of Ordinary Shares as contemplated by
    the Registration Statement.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Option</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&nbsp;option&nbsp;to&nbsp;acquire&nbsp;&nbsp;Option&nbsp;&nbsp;Shares&nbsp;&nbsp;to&nbsp;&nbsp;be
    granted&nbsp;&nbsp;to&nbsp;&nbsp;the&nbsp;&nbsp;Underwriters&nbsp;&nbsp;pursuant&nbsp;&nbsp;to&nbsp;&nbsp;the Underwriting Agreement
    and the Resolutions.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 123pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 123pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Option
    Shares</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 4,054,054 Ordinary Shares or such
    lesser number of Ordinary Shares in respect of which the Option is exercised.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Ordinary
    Shares</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares in the Company's capital,
    with a nominal value of EUR 0.12 each.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Prospectus
    Regulation</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation&nbsp;&nbsp;(EU)&nbsp;&nbsp;2017/1129&nbsp;&nbsp;of&nbsp;&nbsp;the&nbsp;&nbsp;European
    Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted
    to trading on a&nbsp;&nbsp;regulated&nbsp;&nbsp;market,&nbsp;&nbsp;and&nbsp;&nbsp;repealing&nbsp;&nbsp;Directive 2003/71/EC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Registration
    Statement</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company's registration statement on
    Form F-3&nbsp;&nbsp;filed&nbsp;&nbsp;or&nbsp;&nbsp;to&nbsp;&nbsp;be&nbsp;&nbsp;filed&nbsp;&nbsp;with&nbsp;&nbsp;the&nbsp;&nbsp;SEC&nbsp;&nbsp;in
    connection&nbsp;&nbsp;with&nbsp;&nbsp;the&nbsp;&nbsp;Offering&nbsp;&nbsp;in&nbsp;&nbsp;the&nbsp;&nbsp;form reviewed by us.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Relevant
    Moment</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each time when Offer Shares or Option Shares
    are issued pursuant to the execution of a Deed of Issue.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 30%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Resolutions</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the following:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the&nbsp;&nbsp;written&nbsp;&nbsp;resolutions&nbsp;&nbsp;of&nbsp;&nbsp;the&nbsp;&nbsp;General
    Meeting dated 10 August 2020;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>b.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the written resolutions of the Management&nbsp;&nbsp;Board,
    dated 6 February 2023 and 7 February 2023; and</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>c.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the written resolutions of the Supervisory&nbsp;&nbsp;Board,&nbsp;&nbsp;dated&nbsp;&nbsp;6&nbsp;&nbsp;February
    2023; and</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>d.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the&nbsp;&nbsp;written&nbsp;&nbsp;resolutions&nbsp;&nbsp;of&nbsp;&nbsp;the&nbsp;&nbsp;pricing
    committee dated 7 February 2023.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Reviewed
    Documents</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each&nbsp;&nbsp;Deed&nbsp;&nbsp;of&nbsp;&nbsp;Issue&nbsp;&nbsp;and&nbsp;&nbsp;the&nbsp;&nbsp;Underwriting
    Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>SEC</B>&quot;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&nbsp;&nbsp;United&nbsp;&nbsp;States&nbsp;&nbsp;Securities&nbsp;&nbsp;and&nbsp;&nbsp;Exchange
    Commission.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 123pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="tm236242d1_ex5-1img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 123pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;<B>Supervisory Board</B>&quot;</FONT></TD>
    <TD STYLE="width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&nbsp;&nbsp;Company's&nbsp;&nbsp;supervisory&nbsp;&nbsp;board&nbsp;&nbsp;(<I>raad&nbsp;&nbsp;van
    </I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif">commissarissen</FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif">).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;<B>Underwriters</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriters, as defined in the Underwriting </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;<B>Underwriting Agreement</B>&quot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The draft underwriting agreement to be entered into
    between the Company and the Underwriters in&nbsp;&nbsp;connection&nbsp;&nbsp;with&nbsp;&nbsp;the&nbsp;&nbsp;Offering,&nbsp;&nbsp;in&nbsp;&nbsp;the&nbsp;&nbsp;form
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">reviewed by us.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>4
<FILENAME>tm236242d1_ex8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 8.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">ATTORNEYS
 &bull; CIVIL LAW NOTARIES &bull; TAX ADVISERS</TD>
  <TD STYLE="width: 50%"><IMG SRC="tm236242d1_ex8-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">P.O. Box 7113&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1007 JC Amsterdam&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">Beethovenstraat 400</TD>
  <TD STYLE="padding-left: 0.375in; width: 50%">Amsterdam, 10 February 2023.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1082 PR Amsterdam&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T +31 20 71 71 000&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">F +31 20 71 71 111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">We have acted as tax counsel as to
Dutch law to the Company in connection with the Offering and the filing of the Registration Statement with the SEC. This opinion letter
is rendered to you in order to be filed with the SEC as an exhibit to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Capitalised terms used in this opinion
letter have the meanings set forth in Exhibit A to this opinion letter. The section headings used in this opinion letter are for convenience
of reference only and are not to affect its construction or to be taken into consideration in its interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">This opinion letter is strictly limited
to the matters stated in it and may not be read as extending by implication to any matters not specifically referred to in it. Nothing
in this opinion letter should be taken as expressing an opinion in respect of any representations or warranties, or other information,
contained in any document reviewed by us in connection with this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In rendering the opinion expressed in
this opinion letter, we have reviewed and relied upon a draft of the Registration Statement. We have not investigated or verified any
factual matter disclosed to us in the course of our review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">This opinion letter sets out our opinion
on certain matters of the tax laws with general applicability of the Netherlands, and, insofar as they are directly applicable in the
Netherlands, of the European Union, as at today's date and as presently interpreted under published authoritative case law of the Dutch
courts, the General Court and the Court of Justice of the European Union. We do not express any opinion on Dutch or European law other
than the tax opinion below. No undertaking is assumed on our part to revise, update or amend this opinion letter in connection with or
to notify or inform you of, any developments and/or changes of Dutch law subsequent to today's date. We do not purport to opine on the
consequences of amendments to the Registration Statement subsequent to the date of this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The opinion expressed in this opinion
letter is to be construed and interpreted in accordance with Dutch tax law. The competent courts at Amsterdam, the Netherlands, have exclusive
jurisdiction to settle any issues of interpretation or liability arising out of or in connection with this opinion letter. Any legal relationship
arising out of or in connection with this opinion letter (whether contractual or non-contractual), including the
above submission to jurisdiction, is governed by Dutch law and shall be subject to the general terms and conditions of NautaDutilh. Any
liability arising out of or in connection with this opinion letter shall be limited to the amount which is paid out under NautaDutilh's
insurance policy in the matter concerned. No person other than NautaDutilh may be held liable in connection with this opinion letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All legal relationships are subject
to NautaDutilh N.V.&rsquo;s general terms and conditions (see https://www.nautadutilh.com/terms), which apply mutatis mutandis to our relationship
with third parties relying on statements of NautaDutilh N.V., include a limitation of liability clause, have been filed with the Rotterdam
District Court and will be provided free of charge upon request. NautaDutilh N.V.; corporate seat Rotterdam; trade register no. 24338323.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%"><IMG SRC="tm236242d1_ex8-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In this opinion letter and in the Dutch Tax Section,
legal and tax concepts are expressed in English terms. The Dutch legal and tax concepts concerned may not be identical in meaning to the
concepts described by the English terms as they exist under the law of other jurisdictions. In the event of a conflict or inconsistency,
the relevant expression shall be deemed to refer only to the Dutch legal and tax concepts described by the English terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">For the purposes of this opinion letter, we have assumed that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in; text-align: left">a.</TD><TD STYLE="text-align: justify">the Registration Statement has been or will be declared effective
by the SEC in the form reviewed by us; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.5in; text-align: left">b.</TD><TD STYLE="text-align: justify">the place of effective management of the Company is in Germany,
and not in the Netherlands, and the Company will therefore be a tax resident of Germany under German domestic tax law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Based upon and subject to the foregoing and subject
to any matters, documents or events not disclosed to us, we express the following opinion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><B>Dutch Tax Section</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Dutch Tax Section constitutes our opinion
and we hereby confirm that with respect to the matters of Dutch tax law referred to therein, it is accurate and set forth in full as per
the date of the Registration Statement, subject to the introduction in the first paragraphs of the Dutch Tax Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">We consent to the filing of this opinion letter
as an exhibit to the Registration Statement and also consent to the reference to NautaDutilh in the Registration Statement under the caption
 &quot;Legal Matters&quot;. In giving this consent we do not admit or imply that we are a person whose consent is required under Section
7 of the United States Securities Act of 1933, as amended, or any rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Sincerely yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">/s/ NautaDutilh N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"></TD>
  <TD STYLE="width: 50%"><IMG SRC="tm236242d1_ex8-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT A</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIST OF DEFINITIONS</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">"<B>Commercial Register</B>"</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Dutch Commercial Register (<I>handelsregister</I>).</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">"<B>Company</B>"</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac N.V., a public company with limited liability (<I>naamloze vennootschap</I>), registered with the Commercial Register under number 77798031.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Dutch Tax Section</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The statements contained in the Registration Statement under the caption &quot;<I>Taxation</I>&mdash; <I>Material Dutch Tax Considerations</I>&quot;.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>NautaDutilh</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NautaDutilh N.V.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>the Netherlands</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The European territory of the Kingdom of the Netherlands and &quot;<B>Dutch</B>&quot; is in or from the Netherlands.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Offering</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The offering of Ordinary Shares as contemplated by the Registration Statement.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Ordinary Shares</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares in the Company&rsquo;s capital, with a nominal value of EUR 0.12 each.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>Registration Statement</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s registration statement on Form F-3 filed or to be filed with the SEC in connection with the Offering in the form reviewed by us.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;<B>SEC</B>&quot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The United States Securities and Exchange Commission.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>5
<FILENAME>tm236242d1_ex8-2.htm
<DESCRIPTION>EXHIBIT 8.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 8.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;<IMG SRC="tm236242d1_ex8-2img001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 70%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pierre Kemula</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac AG</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Friedrich-Miescher-Str. 15</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">72076 T&uuml;bingen</P></TD>
    <TD STYLE="text-align: left; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>FALK GmbH &amp; Co KG</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Postfach 10 22 80</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><I>69012 Heidelberg </I> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><I>Im Breitspiel 21</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>69126 Heidelberg</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Telefon: +49 6221 399-0</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>Telefax: +49 6221 399-238</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>falk-heidelberg@falk-co.de</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><I>February 10, 2023</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><I>Me /Mth/Ar</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><I>15819 57144986&nbsp;</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-right: 7.1pt; padding-bottom: 8pt; padding-left: 7.1pt; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>US SEC Prospectus Supplement dated February 7, 2022 relating
to Form F-3 Registration Statement of CureVac N.V. (File No. 333-259613)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Kemula,<BR>
<BR>
We act as German Tax Advisors to the Issuer in connection with the Registration. Certain terms used in this opinion are defined in Annex
1 (Definitions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is limited to German tax law in effect
on the date of this opinion. This opinion (including all terms used in it) is to be construed in accordance with German tax law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of this opinion, we have examined
the Registration Statement and Prospectus Supplement which we determined to be the only documents relevant to rendering this opinion,
while relying upon the accuracy of the factual statement therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of this opinion, we have made
the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>The
Registration Statement and Prospectus Supplement been or will be filed with the SEC in the forms referred to in this opinion.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>The
effective place of management of the Issuer is located in T&uuml;bingen, Germany.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>The
factual statements in the Registration Statement and Prospectus Supplement are true and correct in all respects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #404040; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><B>FALK GmbH &amp; Co
KG </B> Wirtschaftspr&uuml;fungsgesellschaft Steuerberatungsgesellschaft</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #404040"><FONT STYLE="font-size: 7pt">Sitz der Gesellschaft:
Heidelberg | AG Mannheim HRA 702086 | USt.-Identifikations-Nr. DE 258 256 316</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #404040"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #404040"><FONT STYLE="font-size: 7pt">Pers&ouml;nlich haftende
Gesellschafterin: FALK &amp; Co Verwaltungs-GmbH Wirtschaftspr&uuml;fungsgesellschaft Steuerberatungsgesellschaft</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #404040"><FONT STYLE="font-size: 7pt">Sitz der Gesellschaft:
Heidelberg AG Mannheim HRB 705586</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #404040"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 109.1pt 0pt 0; color: #404040"><FONT STYLE="font-size: 7pt"><B>Gesch&auml;ftsf&uuml;hrer:
</B>WP&nbsp;StB&nbsp;Gerhard&nbsp;Meyer, WP&nbsp;StB&nbsp;Dr.&nbsp;Martin&nbsp;Ziegler, StB&nbsp;Gerd&nbsp;Fuhrmann, WP&nbsp;StB&nbsp;Thomas&nbsp;Rohling,
WP&nbsp;StB&nbsp;Markus&nbsp;Schmidtke, WP&nbsp;StB&nbsp;Philip&nbsp;Roth, WP&nbsp;StB&nbsp;Stephan&nbsp;Hilbig, WP&nbsp;CPA&nbsp;Gerhard&nbsp;M&uuml;ller,
WP&nbsp;StB&nbsp;Dr.&nbsp;Stefan&nbsp;Tichy, WP&nbsp;StB&nbsp;Andreas&nbsp;D&ouml;rschell, WP&nbsp;StB&nbsp;RA&nbsp;Dr.&nbsp;Steffen&nbsp;Bangert,
WP&nbsp;StB&nbsp;Dr.&nbsp;Alexander&nbsp;W&uuml;nsche, WP&nbsp;StB&nbsp;CPA&nbsp;Steffen&nbsp;Ahrens, WP&nbsp;StB&nbsp;Thorsten&nbsp;Bischoff,
WP&nbsp;StB&nbsp;Kathrin&nbsp;Mindnich</FONT></P>
</TD><TD STYLE="width: 2%"></TD><TD STYLE="text-align: center; width: 28%"><IMG SRC="tm236242d1_ex8-2img002.jpg" ALT=""></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>- 2 -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>15819</I></P></TD>
    <TD STYLE="text-align: left; width: 30%">&nbsp;<IMG SRC="tm236242d1_ex8-2img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the documents referred to and the assumptions
made above, we hereby confirm that the statements set forth in the Prospectus Supplement under the section &ldquo;Taxation-Material German
Tax Considerations&rdquo; constitute the opinion of FALK as to the material German tax consequences of purchasing, owning or transferring
the shares in the capital of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is an exhibit to the Form 6-K incorporated
by referende into the Registration Statement and may only be relied upon for the purpose of the Registration. It may not be supplied,
and its contents or existence may not be disclosed, to any person other than as an Exhibit to (and therefore together with) the Registration
Statement and may not be relied upon for any purpose other than the Registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person relying on this opinion agrees, in
so relying, that only FALK shall have any liability in connection with this opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;file
this opinion as an exhibit to the Registration Statement, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>refer to FALK giving this opinion under the heading &ldquo;Taxation-Material German Tax Considerations&rdquo; in the prospectus
supplement include in the Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The previous sentence is no admittance from us
(or FALK) that we are (or FALK is) in the category of persons whose consent for the filing and reference in that paragraph is required
under Section 7 of the Securities Act or any rules or regulations of the SEC promulgated under it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yours faithfully,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gerhard
Meyer</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">/s/ Marco Muth</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gerhard Meyer)</FONT></TD>
    <TD STYLE="width: 33%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Marco Muth)</FONT></TD>
    <TD STYLE="width: 33%; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steuerberater </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steuerberater</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FALK GmbH &amp; Co KG<BR>
Wirtschaftspr&uuml;fungsgesellschaft<BR>
Steuerberatungsgesellschaft</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm236242d1_ex8-2img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>- 3 -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>15819</I></P></TD>
    <TD STYLE="text-align: left; width: 30%">&nbsp;<IMG SRC="tm236242d1_ex8-2img001.jpg" ALT=""></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex 1 &ndash; Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;German Tax&rdquo;</B> means any tax pursuant to Section 3
(1) through to (3) German Fiscal Code (<I>Abgabenordnung</I>) levied by or on behalf of Germany or any of its subdivisions or taxing authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;FALK&rdquo; </B>means FALK GmbH &amp; Co KG Wirtschaftspr&uuml;fungsgesellschaft
Steuerberatungsgesellschaft.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Issuer&rdquo;</B> means CureVac N.V. with corporate
seat in Amsterdam, the Netherlands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Prospectus Supplement&rdquo;</B> means the prospectus supplement
to be filed with the SEC pursuant to the Securities Act on the date hereof (excluding any documents incorporated by reference in it and
any exhibits to it), which relates to the Registration Statement and has been filed in connection with the Issuer&rsquo;s offering of
up to 31,081,082 common shares, nominal value &euro; 0.12 per share, pursuant to an Underwriting Agreement, dated February 7, 2023, among
the Company, Goldman Sachs &amp; Co. LLC, Jefferies LLC and SVB Securities LLC, as representatives of the underwriters named therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Registration Statement&rdquo;</B> means the registration
statement on form F-3 in relation to the Registration to be filed with the SEC on the date hereof (excluding any documents incorporated
by reference in it and any exhibits to it).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;SEC&rdquo;</B> means the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Securities Act&rdquo; </B>means the U.S. Securities Act of
1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm236242d1_ex8-2img003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.3
<SEQUENCE>6
<FILENAME>tm236242d1_ex8-3.htm
<DESCRIPTION>EXHIBIT 8.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="margin: 0; text-align: right"><B>Exhibit 8.3</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 25%">&nbsp;<IMG SRC="tm236242d1_ex8-3img001.jpg" ALT=""></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Davis Polk &amp; Wardwell <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">450 Lexington Avenue<BR>
New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">davispolk.com</P></TD>
    <TD STYLE="font-size: 10pt; width: 25%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-bottom: 0.25in; font-size: 10pt">February 10, 2023</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac N.V.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Friedrich-Miescher-Strasse 15</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">72076 T&uuml;bingen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Germany</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are acting as United States counsel to CureVac N.V., a Dutch public
company with limited liability (<I>n</I>aamloze vennootschap) (the &ldquo;<B>Company</B>&rdquo;), in connection with the preparation of
the prospectus supplement dated February 7, 2023 (the &ldquo;<B>Prospectus Supplement</B>&rdquo;) filed with the United States Securities
and Exchange Commission pursuant to the provisions of the Securities Act of 1933, as amended. The Prospectus Supplement relates to the
Company&rsquo;s Registration Statement on Form F-3 (File No. 333-259613) (the &ldquo;<B>Registration Statement</B>&rdquo;) and has been
filed in connection with the Company&rsquo;s offering (the &ldquo;<B>Offering</B>&rdquo;) of up to 31,081,082 common shares, nominal value
 &euro;0.12 per share, pursuant to an Underwriting Agreement, dated February 7, 2023, among the Company, Goldman Sachs &amp; Co. LLC, Jefferies
LLC and SVB Securities LLC, as representatives of the underwriters named therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, as your counsel, have examined originals or copies of such documents,
corporate records, certificates of public officials and other instruments as we have deemed necessary or advisable for the purpose of
rendering this opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby confirm that our opinion as to the material U.S. federal
income tax consequences to U.S. holders of an investment in the Company&rsquo;s common shares pursuant to the Offering is set forth in
full under the caption &ldquo;Taxation&mdash;Material U.S. Federal Income Tax Considerations for U.S. Holders&rdquo; in the Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are members of the Bar of the State of New York and the foregoing
opinion is limited to the laws of the State of New York and the federal laws of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use of our name under the captions &ldquo;Taxation&mdash;Material
U.S. Federal Income Tax Considerations for U.S. Holders&rdquo; and &ldquo;Legal Matters&rdquo; in the Prospectus Supplement and to the
filing, as an exhibit to the Registration Statement, of this letter. In giving this consent we do not admit that we come within the category
of persons whose consent is required under Section 7 of the United States Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Davis Polk &amp; Wardwell LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>tm236242d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B><IMG SRC="tm236242d1_ex99-1img001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CureVac Announces Closing of $250 million
Follow-on Public Offering of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>T&Uuml;BINGEN,
Germany/ BOSTON, USA &ndash; February 10, 2023</B> <B>&ndash; </B>CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;), a global biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), announced today
the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total
gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by
CureVac.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 7.5pt 0pt 0; background-color: white">Goldman
Sachs &amp; Co. LLC, Jefferies LLC, and SVB Securities LLC acted as bookrunners for the offering. Van Lanschot Kempen (USA) Inc.
acted as lead manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 7.5pt 0pt 0; background-color: white">The offering
was made pursuant to an effective shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on September 17, 2021. A final prospectus supplement and accompanying prospectus relating to and describing the final terms of the offering
has been filed with the SEC and is available from the SEC&rsquo;s website located at www.sec.gov or from Goldman Sachs &amp; Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by
emailing prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York,
New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and SVB Securities LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 7.5pt 0pt 0; background-color: white">This press
release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac
(Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of
expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of
CureVac&rsquo;s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own
proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop
new products in prophylactic vaccines for infectious diseases based on CureVac&rsquo;s second-generation mRNA technology. This
collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine
technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic
vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in
T&uuml;bingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the
U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>CureVac Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">Dr. Sarah
Fakih, Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">T: +49 7071
9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">M: +49 160
90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bettina J&ouml;dicke-Braas, Manager Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T: +49 7071 9883-1087</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><U>bettina.joedicke-braas@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
&ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.
and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services
GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future events or
future results, in contrast with statements that reflect historical facts. In some cases, you can identify such forward-looking statements
by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;seek,&rdquo; &ldquo;project,&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking
statements are based on management&rsquo;s current beliefs and assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability
to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance
on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes
in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in
the company&rsquo;s industry, the effects of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability
to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and
fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements
to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s
control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or
developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information, please reference the
company&rsquo;s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at www.sec.gov<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm236242d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A )X# 2(  A$! Q$!_\0
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MUY)^V-^UMI'[(?PYAUG48);^\OY3;6%E&VTW,@&3EN=J@8R<'J.*^;OV;_\
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M.O:G%)::5;*E[J")J#Q1Q!PI8JBD$#! "G IO0$?<>X4;A7P=\2O^"J/Q%^
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HI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm236242d1_ex8-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex8-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A )X# 2(  A$! Q$!_\0
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MUY)^V-^UMI'[(?PYAUG48);^\OY3;6%E&VTW,@&3EN=J@8R<'J.*^;OV;_\
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M.O:G%)::5;*E[J")J#Q1Q!PI8JBD$#! "G IO0$?<>X4;A7P=\2O^"J/Q%^
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HI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm236242d1_ex8-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex8-2img001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !C (0# 2(  A$! Q$!_\0
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M*L+>>WMM-L[>"<8FBB@15DXQ\P P>..:J?\ "$^'/^@!I?\ X!Q__$U^2/\
MP\"^._\ T.4/_@IM/_C='_#P+X[_ /0Y0_\ @IM/_C='U2IW0O[2H_RO\/\
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M_P!"AX7_ /!%%_\ &Z/;R_D8?5*?_/V)^)?G1_WU_,4>='_?7\Q7[:?\(O\
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MQ'\AP-%=]_PIO5/^?ZS_ /'_ /"C_A3>J?\ /]9_^/\ ^%'UFC_,'U+$?R'
M_K7KWPZ\!_V/&NIW\?\ ISC]W&P_U*G_ -F/Z4WPA\,/[%U#[;J,L5U)'S"D
M8.U3_>.>_I7?UY^*Q2DN2GL>O@<"X/VE5:]$%%%%>6>Z%%%% !1110 4444
M%<KXV\8+H$'V>V97U"0?*.HC']X_T%6O%WBR'PU9\%7O)!B*(G_QX^PKQRZO
M)+VXDGGE\V:0[F=NI-?"<1Y\L%%X7#/]X]W_ "K_ #?X;]CU\%@_;/VD_A_,
MW/\ A/->_P"?\_\ ?M/\*/\ A/->_P"?\_\ ?M/\*Y[</45;TO39]8O8[6U7
M?*Y_!1W)]A7YE3S',*DE"%:;;V7,_P#,]YT:$5=Q5O1'3Z#X@\3>(-06UM[X
M@=9)#$F(U]3Q7J4$;10HC2-*R@ NW4^YK.\.>'[?P[IZV\(W.>9)2.7;U_\
MK5JU^T9-@:^#H7Q51SJ2WNVTO)?JSY;$UH59_NXI)!1117T!QA1110 4444
M%%%% !1110 4444 4Y]/M;J8O-:PROTW21AC^9%,_L>P_P"?&V_[\K_A116+
MHTI.[BON*YI+9A_8^G_\^-M_WY7_  J6WL;:UD)@MXH21@F- I/Y444*C3B[
GQBD_0.:3W9:HHHK8D**** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm236242d1_ex8-2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex8-2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !V (T# 2(  A$! Q$!_\0
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M"/[^V9<#). #SO\ X+)_#BZ\;>+OA%'9Z5?:A#?ZG+;ZD;:W>0>4CP;-Y4'
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G4445T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm236242d1_ex8-2img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex8-2img003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  8 )0# 2(  A$! Q$!_\0
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M;X:Z"^BV.O0Z6]E:6$#VI^S*I\\01[5.)%\W  &0QQU%7&5/ENW^&WO)??\
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M_P *[\3?] :X_P#'?\:/^%=^)AC&C7 _%?\ &BBCZC3[O\/\@'?\*]\4<?\
M$GN>N>J_XTA^'?B<XSH]Q^:_XT44?4:?=_A_D ?\*]\3_P#0'N?3JO\ C0?A
MYXG)R='N"?7*_P"-%%'U&GW?X?Y !^'GB=NNCW![]5_QKNOAI\+Y;6Z&J:W;
A^7)$W^CVKX."/XV_H/QHHK:C@Z<9\V]A'K-%%%>J(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm236242d1_ex8-3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex8-3img001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  8 (,# 2(  A$! Q$!_\0
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MUM<M&,99,Y5\9Y",2.I&.:_._P#X+40"Z_:(^'T).T2>'$0D=LW<PKO?@?\
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9#$UN+QEX$IC);:Q4*6YP6R0 #@%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm236242d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm236242d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ *T# 2(  A$! Q$!_\0
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M URVUAO&7]H7:VGB+2IIDL[.SMGZ7-DA5B#"1@HS%I5=B6W*N/7** /G_P"
M/PBU?P[\1_$WC3QM8:DWCJ]M1ILFIF^CGTV:V24ONMU#[U+MM8K(B[%5(UX0
ML_H_C3P7JFM?$#P5X@TR]6T32EO[6\!/)AN(!M95((9EFB@.#V+?0]S10!\\
M^!?!WQ.^#NC:V9?#VA_$#Q#)!-))XMCU.2WU+5F2-S DT$L;*C%MJA$G$2[B
M5"#Y:Q_%'PD\:ZQ\)],^$EW:7VK&:]TZ_3QI-=Q3)8^3>0W<XEWR"8RJ\<B1
M;$8%6C!*X;'T]10!\[+\$_BGK?Q+UGQE>^,]$T>ZO6GL;-4TQM0?2M,60>5;
MVPD=8UDF \V>5D<LVQ -D2D]]\"?A7JWP:\-WGA>Y\1MXCT"WN#)HKW,"17-
MG XW/;-Y8"&-)"WEA578C*F,("?2Z* /GWXH>#_$GQ=\6>+] T_6;S1[C2X;
M5=,NK36;K3_[.,T+LM\$@XNG$JLOERD(5CQQELXNL_ OQUXP^*FN^)KW6-0T
MK7=*COE\*:K#.DFG!I;;RK5YHO,#@1EW+PB+;)(-Y=AL1?>K;P58VGQ U#Q;
M')<#4K_3+?3)XO,'D&."6:2-MN/OYN)!G/3 QQ714 ?-.E?#7Q7\,_!JZKK>
MJI::@9+#3+Z\M-5N=0NI+22]C:YGGO9T21WP[A,(H@C+A#R-N]H'PG\>>'].
MTU/[6MFN6UA[P6\5U/=VNE*=-N8 \;7+&613</%(8R<#<P'<GNOC]H\/B#X%
M_$/3KAI(XKGP_?QF2%MKI_H[X93CA@<$'U KHO U]/J7@GP_>74AFN;C3[>6
M61NKNT:EB?J2: /&/@3\!8M+;QOJ/C;PQY/B/Q-%:V>KJ\\-S87<<"N%:%UQ
M*^7DDD:2X42Y=1T10/6-#^%GA?P_-<S6^EBYN+A8TEN-2GDO92B A$WS,[!5
-W'"@X&3ZUU=% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
